Official Title: A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-
Band Ultraviolet B Phototherapy in Participants With Vitiligo  
Study ID: [REMOVED]  
Document 
Date:Clinical Study Protocol Original Version: [ADDRESS_630665]:  Ruxolitinib Cream  
IND Number:  77,101  
Phase of Study:  2 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, Delaware, [LOCATION_003] [ZIP_CODE]  
Original Protocol:  [ADDRESS_630666] their origin in the Declaration of 
Helsinki and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws 
and country -specific regulations in which the study is being conducted.  
The information in this  document is confidential. No part of this information may be duplicated, referenced, or 
transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written consent.  

Incyte Corporation  Version 1  Page 2 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  2 INVESTIGATOR'S AGREEMENT  
I have rea d the INCB [ZIP_CODE] -217 Protocol (dated 30 SEP 2021) and agree to conduct the study as 
outlined. I agree to maintain the confidentiality of all information received or developed in 
connection with this Protocol.  
 
 
   
(Printed Name [CONTACT_7919])    
   
   
(Signature [CONTACT_7919])   (Date)  
Incyte Corporation  Version 1  Page 3 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  3 TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...1 
INVESTIGATOR'S AGREE MENT  ................................ ................................ ................................ [ADDRESS_630667] OF ABBREVIATION S ................................ ................................ ................................ .......... 8 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 10 
2. INTRODUCTION  ................................ ................................ ................................ ......18 
2.1. Ruxolitinib Cream  ................................ ................................ ................................ ......18 
2.2. Background  ................................ ................................ ................................ ................. 18 
2.3. Clinical Efficacy and Safety Data With Ruxolitinib Cream  ................................ .......19 
2.4. Study Rationale  ................................ ................................ ................................ ........... 20 
2.5. Justification for Strength of Rux olitinib Cream  ................................ ......................... 21 
2.6. Justification for Dose of Narrow -Band Ultraviolet B Phototherapy  .......................... 21 
2.7. Benefit/Risk Assessment  ................................ ................................ ............................ 22 
3. OBJECTIVES AND ENDPOI NTS  ................................ ................................ ............ 23 
4. STUDY DESIGN  ................................ ................................ ................................ .......25 
4.1. Overall Design  ................................ ................................ ................................ ............ 25 
4.2. Overall Study Duration  ................................ ................................ ............................... 25 
4.3. Study Termination  ................................ ................................ ................................ ......25 
5. STUDY POPULATION  ................................ ................................ ............................. 26 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ........ 26 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......26 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 29 
5.4. Screen Failures  ................................ ................................ ................................ ............ 29 
5.5. Replacement of Participants  ................................ ................................ ....................... 29 
6. STUDY TREATMENT  ................................ ................................ .............................. 29 
6.1. Study Treatments Administered  ................................ ................................ ................. 29 
6.2. Preparation, Handling, and Accountability  ................................ ................................ 31 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ........ [ADDRESS_630668] to Follow -Up................................ ................................ ................................ .......38 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 39 
8.1. Administrative and General Procedures  ................................ ................................ .....39 
8.1.1.  Informed Consent Process  ................................ ................................ .......................... 39 
8.1.2.  Screening Procedures  ................................ ................................ ................................ ..40 
8.1.3.  Interactive Response Technology Procedure  ................................ .............................. 40 
8.1.4.  Distribution of Study Reminder Cards and Diaries  ................................ .................... 40 
8.1.5.  Demography and Medical History  ................................ ................................ .............. 41 
[IP_ADDRESS].  Demographics and General Medical History  ................................ ............................. 41 
[IP_ADDRESS].  Disease Characteristics and Treatment History  ................................ .......................... 41 
8.2. Efficacy Assessments  ................................ ................................ ................................ .41 
8.2.1.  Body Surface Area  ................................ ................................ ................................ ......41 
8.2.2.  Vitiligo Area Scoring Index  ................................ ................................ ........................ 41 
 42 
 43 
8.2.5.  Photography  ................................ ................................ ................................ ................ 43 
 43 
 .44 
 .44 

Incyte Corporation  Version 1  Page 5 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  5  .44 
 .45 
 45 
 45 
 45 
 46 
8.3. Safety Assessments  ................................ ................................ ................................ .....46 
8.3.1.  Adverse Events  ................................ ................................ ................................ ........... 46 
8.3.2.  Physi cal Examinations  ................................ ................................ ................................ 46 
8.3.3.  Vital Signs  ................................ ................................ ................................ .................. 47 
8.3.4.  Electrocardiograms  ................................ ................................ ................................ .....47 
8.3.5.  Laboratory Assessments  ................................ ................................ ............................. 47 
[IP_ADDRESS]. Pregnancy Testing  ................................ ................................ ................................ ......49 
[IP_ADDRESS].  Serology  ................................ ................................ ................................ ...................... 49 
8.4. Pharmacokinetic Assessments  ................................ ................................ .................... 49 
 49 
8.6. Unscheduled Visits  ................................ ................................ ................................ .....50 
8.7. End of Treatment and/or Early Termination  ................................ .............................. 50 
8.8. Safety Follow -Up ................................ ................................ ................................ ........ 50 
9. ADVERSE E VENTS: DEFINITIONS A ND PROCEDURES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  ...................... 51 
9.1. Definition of Adverse Event  ................................ ................................ ....................... 51 
9.2. Definition of Serious Adverse Event  ................................ ................................ .......... 51 
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse Events  ......... [ADDRESS_630669] Complaints  ................................ ................................ ................................ ....57 
9.10.  Treatment of Overdose  ................................ ................................ ............................... 58 
10. STATISTICS  ................................ ................................ ................................ .............. 59 
10.1.  Sample Size Determination  ................................ ................................ ........................ 59 

Incyte Corporation  Version 1  Page 6 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  6 10.2. Populations for Analysis  ................................ ................................ ............................. 59 
10.3.  Level of Significance  ................................ ................................ ................................ ..59 
10.4.  Statistical Analyses  ................................ ................................ ................................ .....59 
10.4.1.  Efficacy Analysis  ................................ ................................ ................................ ........ 60 
[IP_ADDRESS] . Analysis of Primary Efficacy Analysis  ................................ ................................ .......60 
[IP_ADDRESS].  Analysis of Secondary Efficacy Endpoints  ................................ ................................ [ADDRESS_630670] OF TABLES  
Table  1: Primary Objective and Endpoint  ................................ ................................ ................ 10 
Table  2: Key Study Design Elements  ................................ ................................ ....................... 10 
Table  3: Schedule of Assessments for Screening Through Week 12  ................................ .......12 
Table  4: Schedule of Assessments Week 16 Through End of Study  ................................ ........ 15 
Table  5: Objectives and Endpoints  ................................ ................................ ........................... 23 
Incyte Corporation  Version 1  Page 7 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  7 Table  6: Study Treatment Information (Ruxolitinib Cream)  ................................ .................... 30 
Table  7: Study Treatment Information (NB -UVB)  ................................ ................................ ..30 
Table  8: Guidelines for Interruption and Restarting of Study  Cream  ................................ .......33 
Table  9: NB-UVB Dose Adjustments Based on the Skin Assessments  ................................ ...34 
Table  10: NB-UVB Dose Adjustments for Missed Treatments  ................................ ................. 34 
 42 
 .43 
Table  13: Required Laboratory Analytes  ................................ ................................ .................... 48 
Table  14: Populations for Analysis  ................................ ................................ ............................. 59 
Table  15: Safety Analyses  ................................ ................................ ................................ .......... [ADDRESS_630671] OF FIGURES  
Figure  1: Study Design Schema  ................................ ................................ ................................ .[ADDRESS_630672]  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
EOS  end of study  
EOT  end of treatment  
F-BSA  facial body surface area  
  
  
FAS full analysis set  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
F-VASI  Face Vitiligo Area Scoring Index  
F-VASI25/50/75/90  ≥ 25%/ 50%/ 75%/ 90% improvement from baseline in Face Vitiligo Area 
Scoring Index score  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulation  
HIPAA  Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
HRT  hormone replacement therapy  
IB Investigator's Brochure  
ICF informed consent form  
ICH International Conference on Harmonisation  
ID identification  
IEC independent ethics committee  
IRB institutional review board  

Incyte Corporation  Version [ADDRESS_630673] operating procedure  
SPF sun protection factor  
S[LOCATION_003]R  suspected unexpected adverse reaction  
T-BSA  total body surface area  
TEAE  treatment -emergent adverse event  
  
T-PaGVA  total body assessment of Patient's Global Vitiligo Assessment  
  
TSH  thyroid -stimulating hormone  
T-VASI  total body Vitiligo Area Scoring Index  
T-VASI25/50/75/90  ≥ 25%/ 50%/ 75%/ 90% improvement in total body Vitiligo Area Scoring Index  
TYK  tyrosine kinase  
ULN  upper limit of normal  
UV ultraviolet  
VASI  Vitiligo Area Scoring Index  
  
  
WHO  World Health Organization  
  
WOCBP  women of childbearing potential  

Incyte Corporation  Version 1  Page 10 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  10 1. PROTOCOL SUMMARY  
Protocol Title:  
A Safety and Efficacy Study of  Ruxolit inib Cream Combined With Narrow -Band Ultraviolet B 
Phototherapy in Participants With Vitiligo  
Protocol Number : INCB [ZIP_CODE] -217 
Objectives and Endpoints:  
Table  1 presents the primary objective and endpoint.  
Table  1: Primary Objective and Endpoint  
Objective  Endpoint  
Primary  
To evaluate the efficacy of ruxolitinib cream in 
combination with NB -UVB in participants with 
vitiligo . Change from baseline in T -VASI at Week 48 . 
Overall Design:  
Table  2 presents the key study design elements. Further study details are presented after the 
table.  
Table  2: Key Study Design Elements  
Study Phase  Phase 2  
Clinical Indication  Patients with nonsegmental vitiligo  
Population  Males and female participants, aged ≥ [ADDRESS_630674] vitiligo with 
≥ 0.5 F-VASI, ≥  3.0 T-VASI ( body areas not including the face), and total 
body vitiligo area (facial and nonfacial) not exceed ing 10% BSA.  
Number of 
Participants  Approximately 50 participants  will receive ruxolitinib 1.5% cream BID  
Study Design  Open -label  
Estimated Duration 
of Study 
Participation  Screening : Up to 30 days 
Treatment period : 48 weeks  
Safety follow -up: [ADDRESS_630675] study visit  
Total : Up to approximately 56 weeks  
DSMB/DMC  No 
Coordinating 
Principal 
Investigator   

[INVESTIGATOR_490500] 1  Page 11 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  11 Treatment Groups and Duration:  
This is an open -label study in which participants will apply  ruxolitinib 1.5% cream BID to all 
depi[INVESTIGATOR_490501] 10% BSA for up to 48 weeks. Participants should continue to treat 
depi[INVESTIGATOR_490502] s to 
improve or fully repi[INVESTIGATOR_2517] . 
On Day 1, all participants  will apply ruxolitinib 1.5% cream BID as monotherapy. At Week  12, 
participants will apply ruxolitinib 1.5% cream alone or in combination with NB -UVB based on 
improvement in T -VASI score. Participants who have < T -VASI25 will have NB -UVB  
phototherapy added to their  ruxolitinib 1.5% cream BID regimen  (Group A) . NB -UVB  will be 
given 3  times per week through Week 48  (36 weeks). Participants who have ≥  T-VASI25 at 
Week 12 will continue on ruxolitinib 1.5% cream BID alone (Group B). For partic ipants who 
receive combination therapy, NB -UVB machines will be supplied by [CONTACT_490533].  
Figure  1 presents the study design schema. Table  3 presents the schedule of activities for the 
mono therapy portion of the study (screening through Week 12). Table  4 presents the schedule of 
activities for Week 16 through the end of the study.  
Figure  1: Study Design Schema  
 
 

Incyte Corporation  Version 1  Page 12 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  12 Table  3: Schedule of Assessments for Screening Through Week 12  
Procedure  Screening  Treatment Run -In  
Days  
−30 to −1 Day 1  Week 4  
(± 3 d ) Week 8  
(± 3 d ) Week 12  
(± 3 d ) Notes  
Administrative procedures   
Informed consent  X     Section  8.1.[ADDRESS_630676] IRT  X X X X X Section  8.1.3   
Inclusion and exclusion criteria  X X    Section  5  
Demography  X     Section [IP_ADDRESS]   
General and vitiligo medical history  X     Section [IP_ADDRESS]   
Prior/concomitant medications  X X X X X Section  6.[ADDRESS_630677] 
supervision of the site staff.  Study cream should be 
applied after PK or translational blood draws on 
applicable days.  
Dispense (D) and return (R) study cream 
and reminder/ diary cards   D R/D R/D R/D All tubes  of study drug to  be weighed  before dispensing 
and when  returned. Tubes may not be redispensed.  
Collect study cream tubes and 
collect/review study cream diary cards    X X X  
Assess compliance of study cream    X X X Compliance is based on the number of applications. 
Section  6.4. 
Safety assessments   
AE assessmen t* X X X X X *If an AE is noted, relevant body systems should be 
physically examined in a targeted physical exam.  
Section  8.3.2  
Ad hoc photography of skin -related AEs should occur as 
applicable. Section  8.2.5  
Comprehensive physical examination  X    X Section  8.3.2   
Vital signs  X X X X X Section  8.3.3   
12-lead ECG  X     12-lead ECG performed within 2 months before baseline 
is acceptable. Section  8.3.4  
Incyte Corporation  Version 1  Page 13 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  13 Table  3: Schedule of Assessments for Screening Through Week 12 (Continued)  
Procedure  Screening  Treatment Run -In  
Days  
−30 to −1  Day 1  Week 4  
(± 3 d)  Week 8  
(± 3 d)  Week 12  
(± 3 d)  Notes  
Efficacy assessments   
F-BSA  X X X X X Section  8.2.1   
T-BSA  X X X X X Includes facial and nonfacial areas. Section  8.2.1   
F-VASI  X X X X X Section  8.2.2   
T-VASI  X X X X X Includes facial and nonfacial areas. Section  8.2.2   
Photography of face  X X*   X *If photo quality at screening is not adequate, the 
photography may be repeated on Day 1. Section  8.2.5   Photography of nonfacial target area  X X*   X 
Laboratory assessments   
Hematology and chemistry assessments  X X   X Section  8.3.5   
Serology and thyroid testing  X     Section  [IP_ADDRESS]   
Urinalysis  X     Section  8.3.5   
FSH X      
Pregnancy testing  (serum)  X     Section  [IP_ADDRESS]   
Pregnancy testing (urine)   X X X X Section  [IP_ADDRESS]  

Incyte Corporation  Version 1  Page 14 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  14 Table  3: Schedule of Assessments for Screening Through Week 12 (Continued)  
Procedure  Screening  Treatment Run -In  
Days  
−30 to −1  Day 1  Week 4  
(± 3 d)  Week 8  
(± 3 d)  Week 12  
(± 3 d)  Notes  
PK and translational assessments   
PK blood draw    X  X Blood samples must not be drawn from the area that has 
been treated with study cream.  
Samples will be drawn at preapplication. Section  8.4  
Vitamin D assessment  X X   X  
Note : Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical and laboratory tests may be performed, as clinically indicated.  

Incyte Corporation  Version 1  Page 15 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  15 Table  4: Schedule of Assessments Week 16 Through End of Study  
Procedure   Safety 
Follow -Up Notes  
Week 16  
(± 3 d ) Week 24  
(± 7 d ) Week 32  
(± 7 d ) Week 40  
(± 7 d ) Week 48  
(EOT)  
(± 7 d ) 30 days  
(EOT*+7 d ) 
(EOS)  *After last application of study cream or last visit.  
Administrative procedures   
Contact [CONTACT_12067]  X X X X X X Section  8.1.3   
Prior/concomitant medications  X X X X X X Section  6.[ADDRESS_630678] 
supervision of the site staff. Study cream should be applied 
after PK or translational blood draws on applicable  days.  
Dispense (D) and return (R) study 
cream and reminder/ diary cards  R/D R/D R/D R/D R  All tubes of study drug to be weighed before dispensing  and 
when returned.  Tubes may not be redispensed.  
Collect study cream tubes and 
collect/review study cream diary 
cards  X X X X X   
Assess compliance  of study 
cream  X X X X X  Compliance is based on the number of applications. 
Section  6.4  
Assess compliance with NB -UVB  X X X X X  Compliance is based on the number of sessions  recorded by 
[CONTACT_490534] -UVB machine . Section  6.4  
Safety assessments   
AE assessment*  X X X X X X *If an AE is noted, relevant body systems should be 
physically examined  in a targeted physical exam . 
Section  8.3.2  
Ad hoc photography of skin -related AEs may occur as 
applicable . Section  8.2.5  
Comprehensive physical 
examination   X   X  Section  8.3.2   
Vital signs  X X X X X X Section  8.3.3   
Incyte Corporation  Version 1  Page 16 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  16 Table  4: Schedule of Assessments Week 16 Through End of Study (Continued)  
Procedure   Safety 
Follow -Up Notes  
Week 16  
(± 3 d)  Week 24  
(± 7 d)  Week 32  
(± 7 d)  Week 40  
(± 7 d)  Week 48  
(EOT)  
(± 7 d)  30 days  
(EOT*+7 d)  
(EOS)  *After last application of study cream or last visit.  
Efficacy assessments   
F-BSA  X X X X X X Section  8.2.1   
T-BSA  X X X X X X Includes facial and nonfacial areas. Section  8.2.1  
F-VASI  X X X X X X Section  8.2.2   
T-VASI  X X X X X X Includes facial and nonfacial areas. Section  8.2.2   
Photography of face   X  X X  Section  8.2.5   
Photography of nonfacial target 
area  X  X X  
Laboratory assessments    
Hematology and chemistry 
assessments   X  X X  Section  8.3.5   
Pregnancy testing (serum)       X Section  [IP_ADDRESS]  
Pregnancy testing  (urine)  X X X X X  Section  [IP_ADDRESS]  

Incyte Corporation  Version 1  Page 17 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  17 Table  4: Schedule of Assessments Week 16 Through End of Study (Continued)  
Procedure   Safety 
Follow -Up Notes  
Week 16  
(± 3 d)  Week 24  
(± 7 d)  Week 32  
(± 7 d)  Week 40  
(± 7 d)  Week 48  
(EOT)  
(± 7 d)  30 days  
(EOT*+7 d)  
(EOS)  *After last application of study cream or last visit.  
PK and translational assessments   
PK blood draw  X*      Blood samples must not be drawn from an area that has been 
treated with study cream.  
Samples will be drawn at preapplication. Section  8.4 
*Only participants starting combination at Week 12.  
Vitamin D assessment   X  X X X  
Note : Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical and laboratory tests may be performed, as clinically indicated.  

Incyte Corporation  Version [ADDRESS_630679] 
TYK2 and JAK3. Ruxolitinib  potently (IC 50 < 5 nM) inhibits JAKs, yet it does not significantly 
inhibit (< 30% inhibition) a broad panel of 26 kinases when tested at 200 nM (approximately 
100 times the average IC 50 value for JAK enzyme inhibition). Ruxolitinib -mediated inhibition of  
JAK signaling may be an effective strategy for vitiligo treatment.  
2.2. Background  
Vitiligo is an autoimmune pi[INVESTIGATOR_490503] 0.5% to 2% of the 
population worldwide ( Krüger and Schallreuter 2012 ) and  is characterized by [CONTACT_61911][INVESTIGATOR_490504] a selective loss of melanocytes. The natural course of the disease is 
generally unpredictable, but it is often progressive. Some degree of spontaneous repi[INVESTIGATOR_490505] 10% to 20% of patients;  however, it is typi[INVESTIGATOR_352832] 
(Castanet and Ortonne 1997 ). 
Vitiligo is considered a serious disease owing to its substantial psychological burden on patients 
and its progressive course if left untreat ed. Involvement of exposed skin (eg, face and hands) can 
have a major negative impact on self -esteem and quality of life ( Silverberg and Silverberg 2013 ). 
Currently, there is no approved drug  treatment for repi[INVESTIGATOR_490506]. The management 
of vitiligo is empi[INVESTIGATOR_352834] ( American Academy 
of Dermatology , Gawkrodger et al 2008 , Taieb et al 2013 , Vitiligo Research Foundation ). In 
general, first -line treatments consist of topi[INVESTIGATOR_304266], which may be 
most useful for treating disease that is localized . However, this use is off -label, there are 
inconclusive (or insufficient) data supporting their efficacy, many have restrictions on duration 
of chronic use, and AEs can limit their tolerability. Second -line treatments consist of 
phototherapy (NB -UVB and P UVA) and systemic steroid treatment. However, phototherapy 
regimens typi[INVESTIGATOR_1435] 2 to 3 treatments per week, and 12 to 24 months of continuous 
phototherapy may be necessary to acquire maximal repi[INVESTIGATOR_371] ( Taieb et al 2 013); relapses 
are common. Third -line treatments consist of surgical grafting techniques and depi[INVESTIGATOR_490507]. Surgery is best indicated for stable and localized forms of vitiligo, and only a small 
number of patients with vitiligo are considered sui table candidates. All of these treatments can 
have adverse effects that limit their use.  
No available product or therapy is able to modify the course of vitiligo disease and produce a 
long-lasting effect. Given the lack of approved therapi[INVESTIGATOR_014] , safety concerns , and modest 
effectiveness of current off -label drug treatments, there is a need to identify a safe and effective 
new treatment for vitiligo.  
Incyte Corporation  Version 1  Page 19 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  19 2.3. Clinical Efficacy and Safety Data With Ruxolitinib Cream  
The clinical efficacy and safety of ruxol itinib cream in vitiligo has been evaluated in over 
800 participants in 3 randomized, vehicle -controlled studies, 1 Phase 2 (157 participants) and 
2 Phase 3 studies (674 participants).  
Study INCB [ZIP_CODE] -211 evaluated 4 regimens of ruxolitinib cream (1.5% BI D, 1.5% QD, 
0.5%  QD, 0.15% QD) versus vehicle BID for 24 weeks in adults. In INCB [ZIP_CODE] -211, all 
participants initially randomized to vehicle BID and participants initially randomized to 
0.15%  QD who did not achieve ≥ 25% improvement from baseline i n F-VAS I25 were 
rerandomized to 1  of the 3  higher strength groups for an additional 28 weeks. All other 
participants maintained in the same treatment until Week 52. After Week 52, participants could 
receive open -label 1.5% BID for an additional 104 weeks. The pri mary endpoint was the 
proportion of participants who achieved a ≥  50% improvement from baseline in F -VASI50 at 
Week 24.  
In Study INCB [ZIP_CODE] -211, all ruxolitinib treatment groups demonstrated clinically meaningful 
efficacy and superiority over vehicle. The proportion of participants who achieved an F -VASI50 
at Week 24 was statistically significantly greater for ruxolitinib cream versus vehicle with 
response rates of 32.3%, 25.8%, 50.0%, and 45.5% for ruxolitinib cream 0.15% QD, 0.5% QD, 
1.5% QD, and 1.5% BID , respectively, and 3.1% for vehicle. The proportion of participants who 
achieved an F -VASI75 at Week 24 was also statistically significantly greater for ruxolitinib 
cream versus vehicle with response rates of 9.7%, 16.1%, 16.7%, and 30.3% for ruxolitinib 
cream 0.15% QD, 0.5% QD, 1.5% QD, and 1.5% BID, respectively, and 0% for vehicle.  
In Study INCB [ZIP_CODE] -211, improvements in T -VASI were observed at both Weeks 24 and 52. 
The proportion of participants who achieved a T -VASI50 at Week 24 was also statisticall y 
significantly greater for ruxolitinib cream 0.15% QD, 0.5% QD, 1.5% QD, and 1.5% BID 
compared with vehicle with response rates of 16.1%, 6.5%%, 23.3%, and 12.1%, respectively, 
compared with 0% in vehicle treated participants. Continued improvement in par ticipants treated 
with 0.5% QD, 1.5% QD, and 1.5% BID through Week 52 was observed with response rates in 
T-VASI50 of 25.8%, 30.0%, and 36.4%, respectively.  
In participants with vitiligo in Study [ZIP_CODE] -211, the incidence and severity of TEAEs among 
partici pants who applied ruxolitinib cream were generally similar to those in participants who 
applied vehicle cream during the vehicle -controlled period; 67.2% and 62.5% of participants on 
active treatment and vehicle , respectively,  had at least 1 TEAE ; 0.8% and  0% of participants on 
active treatment and vehicle , respectively,  had at least [ADDRESS_630680] 
frequently reported TEAEs in the active treatment groups during the vehicle -controlled period 
were acne (12.0%), application site pruritus (1 0.4%), pruritus (8.8%), and viral upper respi[INVESTIGATOR_19629] (6.4%). The most common events by [CONTACT_490535] a comparable 
incidence for participants on vehicle cream with the exception of acne, which was more common 
in participants on a ctive treatment. With continued exposure for the [ADDRESS_630681] application 
strength groups, acne (14.9%), pruritus (12.8%), application site pruritus (7.4%), and viral upper 
respi[INVESTIGATOR_1092] (10.6%) remained among the most common TEAEs. No serious T EAE 
had a fatal outcome nor were they considered related to the study cream by [CONTACT_093]. 
There were no clinically meaningful changes in chemistry or hematology parameters, and no 
clinically meaningful changes were noted for vital signs.  
Incyte Corporation  Version 1  Page 20 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  20 In Study IN CB [ZIP_CODE] -211, after Week 52, a subset of participants were offered optional 
concomitant NB -UVB phototherapy while continuing open -label treatment with ruxolitinib 1.5% 
cream  BID. Participants could start phototherapy at any time during the open -label perio d. 
Nineteen participants received add -on NB -UVB for ≥ 12 weeks  (Pandya et al 2021 ), with [ADDRESS_630682] common phototherapy regimen. Among these 19 participants, 
15 participants (78.9%) had further improvemen t in F -VASI and 18 participants (94.7%) had 
further improvement in  T-VASI after the addition of NB -UVB to the ruxolitinib cream regimen . 
Only 4  participants  (21%)  who received concomitant NB -UVB therapy had AEs, all of which 
were Grade 1 or 2 in severity and none were related to treatment.  
Studies INCB [ZIP_CODE] -306 and -307 are identically -designed, randomized, vehicle -controlled, 
Phase 3 studies in adolescent and adu lt participants (≥ 12 years old, ~10% of whom were 
adolescents) with vitiligo. Participants received blinded study treatment for 24 weeks and were 
then offered the opportunity to receive an additional 28 weeks of treatment with ruxolitinib 
cream 1.5% BID. NB-UVB therapy was not allowed in the Phase 3 studies.  
Both ongoing Phase 3 studies (INCB [ZIP_CODE] -306 and -307) studies met the primary endpoint 
(p < 0.0001 for both studies), demonstrating that significantly more participants treated with 
ruxolitinib cream 1.5% twice daily (BID) achieved a ≥  75% improvement from baseline in the 
facial vitiligo area scoring index (F -VASI75) compared to participants treated with a vehicle 
control at Week 24. Safety and tolerability in the Phase 3 studies were similar to Study 
INCB  [ZIP_CODE] -211 in that the rate of Grade 3 TEAEs, SAEs, and TEAEs leading to 
discontinuation was low. Further, there were no significant TEAEs or application site events and 
no clinically relevant hematological changes.  
2.4. Study Rationale  
NB-UVB phototherapy is thought to stimulate the proliferation of melanocytes and 
melanogenesis, thereby [CONTACT_490536], which creates a more 
favorable immune environment for melanocyte survival by [CONTACT_490537]. 
In Study INCB 1 8424 -211, the addition of phototherapy to ruxolitinib cream in participants with 
vitiligo was well tolerated; the frequency of adverse events was low, and none were related to 
treatment  (Pandya et al 2021 ). The addition of NB -UVB phototherapy to ruxolitinib cream 
resulted in further substantial improvement in repi[INVESTIGATOR_371], including in participants who did 
not achieve F -VASI50 at Week 24. The current study will investigate these findings in a larger 
study.  
This study is a 2 -part, open -label study examining the addition of NB -UVB to ruxolitinib 1.5% 
cream BID. Approximately 50 participants will receive ruxolitinib 1.5% cream BID for 
12 weeks. At Week 12, participants will be assigned to ruxolitinib 1.5% cream alone or in 
combi nation with NB -UVB (3 times per week through Week 48 ) based on the improvement in 
T-VASI (see Figure  1). Participants who have < T -VASI25 will receive th e combination of 
NB-UVB phototherapy and ruxolitinib 1.5% cream BID (Group A). Participants who have 
≥ T-VASI25 at Week 12 will continue on ruxolitinib 1.5% cream BID alone (Group B).  
Incyte Corporation  Version 1  Page 21 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  21 In Study INCB [ZIP_CODE] -211, 21.2% of participant  who applied  ruxolitinib 1. 5% cream BID 
achieved a T -VASI25 at Week 1 2. T-VASI25 at Week 12 represents a reasonable outcome 
showing that the participant is having a response to ruxolitinib cream and will potentially benefit 
from ruxolitinib cream alone. In participants that do not achieve a T -VASI25 at Week  12, 
NB-UVB will be added to possibly increase the response rate.  
NB-UVB phototherapy administered 3 times per week has been chosen as the regimen for this 
study as this regimen has been shown to induce repi[INVESTIGATOR_371] ( Mohammad et al 2017 ). This 
combination regimen should provide adequate stimulation to the melanocytes to augment the 
repi[INVESTIGATOR_490508].  
The primary purpose of this study is to evaluate mean per centage change from baseline of 
T-VASI at Week 48 . Additionally, a secondary endpoint is the safety and tolerability of 
combination therapy (ruxolitinib cream plus NB -UVB) in participants with vitiligo.  
2.5. Justification for Strength of Ruxolitinib Cream  
Resul ts from Study INCB [ZIP_CODE] -211 showed that ruxolitinib 1.5% cream  BID had the highest 
repi[INVESTIGATOR_490509] F -VASI and T -VASI, particularly at Week 48 . All ruxolitinib 
treatment strengths were generally safe and well tolerated with no significant TEAEs  or 
application site events and no clinically relevant hematological changes. Also, the available data 
for phototherapy combination was with ruxolitinib 1.5% cream  BID. Further, in the 2  Phase  3 
studies, ruxolitinib 1.5% BID showed statistically significan t and clinically meaningful 
improvements for F -VASI and T -VASI compared with vehicle , and the safety profile was similar 
to that seen in the Phase [ADDRESS_630683], NB-UVB stimulates growth and 
migration of remaining perilesional and follicular melanocytes. A combination of N B-UVB and 
ruxolitinib cream may lead to an accelerated rate of repi[INVESTIGATOR_371], and potentially a more 
durable response to treatment.  
NB-UVB phototherapy administered 3 times per week (see Table  7) has been chosen as the 
regimen for this study as this regimen has been shown to induce repi[INVESTIGATOR_371] 
(Mohammad  et al 2017 ); therefore, starting at Week [ADDRESS_630684] < T-VASI25 will 
receive combination therapy of ruxolitinib cream 1.5% BID in combination with NB -UVB 
phototherapy [ADDRESS_630685] ≥ T -VASI25 at Week  12 
will continue to receive ruxolitinib cream monotherapy.  This combination regimen should 
provide adequate stimulation to the melanocytes to augment the repi[INVESTIGATOR_490510].  
Incyte Corporation  Version 1  Page 22 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  22 2.7. Benefit/Risk Assessment  
Results from dermal safety studies to evaluate local tolerability in healthy participants 
demonstrate that ruxolitinib 1.5% cream did not cause sensitization and was only slightly 
irritating under exaggerated testing conditions (occlusive application). In addition, ruxolitinib 
1.5% cream was not phototoxic and did not induce photosensitization.  This was further 
confirmed by [CONTACT_941] a vailable safety data in the Phase 2 and Phase 3 studies where ruxolitinib cream 
was well tolerated at the application sites with infrequently reported application site reactions.  
In participants with vitiligo, all ruxoli tinib treatment strengths were generally safe and well 
tolerated with no significant TEAEs or application site events . The TEAE rate overall was low 
and similar between active treatment and vehicle. Application site acne was noted as an adverse 
drug reacti on in the IB. The rate of TEAEs leading to discontinuation from treatment was low. 
No serious TEAE had a fatal outcome nor were they considered related to the study cream by [CONTACT_1275]. There were no clinically meaningful changes in chemistry or hema tology 
parameters, and no clinically meaningful changes were noted for vital signs.  
A comprehensive analysis of potential safety concerns associated with oral ruxolitinib and other 
oral JAK inhibitors was performed. As expected given the low bioavailability and the low 
plasma concentrations of ruxolitinib observed following topi[INVESTIGATOR_59407], ruxolitinib cream 
was not associated with these safety concerns.  
Narrow -band UVB is generally safe and there were no safety issues with the combination  in the 
small subset of participants in Study INCB [ZIP_CODE] -211. There are no substantial safety issues 
expected.  
Ruxolitinib cream showed statistically significant and clinically meaningful improvement in 
participants with vitiligo  compared with vehicle . Also, among the 19 participants who received 
combination therapy with ruxolitinib 1.5% cream and NB -UVB in Study INCB [ZIP_CODE] -211, 
F-VASI and T -VASI improvements after add -on phototherapy increased for all response 
parameters.  
As ruxolitinib 1.5% cream is gener ally safe and well tolerated and showed clear benefit in the 
Phase 2 and Phase 3 studies, the benefit risk profile is expected to be positive.  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of ruxolitinib cream may be found in the IB. 
Incyte Corporation  Version 1  Page 23 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  23 3. OBJECTIVES AND ENDPO INTS  
Table  5 presents the objectives and endpoints.  
Table  5: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the efficacy of 
ruxolitinib cream in combination 
with NB -UVB in participants with 
vitiligo . • Change from baseline in T -VASI at Week 48 . 
Secondary  
To evaluate the safety and 
tolerability of ruxolitinib cream in 
combination with NB -UVB.  • Occurrence of AEs and evaluation of vital signs and 
laboratory data.  
To further evaluate the efficacy of 
ruxolitinib cream in combination 
with NB -UVB in participants  with 
vitiligo.  • Proportion of participants achiev ing F -VASI50/75/90 at each 
postbaseline visit.  
• Proportion of participants achiev ing T -VASI50/75/90 at each 
postbaseline visit.  
• Change and percentage change from baselin e in 
F-VASI/T -VASI at each post baseline  visit.  
• Change and percentage change from basel ine in 
F-BSA/T -BSA at each post baseline visit.  
To evaluate the ruxolitinib PK in 
plasma after treatment with 
ruxolitinib cream in combination 
with NB -UVB.  • Population -based (trough) plasma concentrations of 
ruxolitinib at Weeks 4 , 12, and 16 . 
Incyte Corporation  Version 1  Page 24 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  24 Table  5: Objectives and Endpoints (Continued)  
Objectives  Endpoints  

Incyte Corporation  Version 1  Page 25 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  25 4. STUDY DESIGN  
4.1. Overall Design  
This is an open -label study in which participants will apply ruxolitinib 1.5% cream BID to all 
depi[INVESTIGATOR_490501] 10% BSA for up to 48  weeks. Participants should continue to treat 
depi[INVESTIGATOR_490511] . 
On Day 1, all participants will apply ruxolitinib 1.5% cream BID as monotherapy (see Figure  1). 
At W eek 12, participants will apply ruxolitinib 1.5% cream alone or in combination with 
NB-UVB based on improvement in T -VASI score. Participants who have < T -VASI25 will have 
NB-UVB phototherapy added to their ruxolitinib 1.5% cream BID regimen (Group A). NB -UVB 
will be given 3  times per week through Week 48 (36  weeks). Participants who have ≥  T-VASI25 
at Week 12 will continue on ruxolitinib 1.5% cream BID alone (Group B). For participants who 
receive combination therapy, NB -UVB machines will be supplied by [CONTACT_3433] e sponsor for at home use 
during the study.  
At any time during the study, if vitiligo areas become significantly more extensive than from the 
previous visit, the participant should contact [CONTACT_490538]. Participants who have  expansion of areas 
of vitiligo  identified at baseline or new areas of vitiligo  during the course of the treatment period 
should not treat the additional areas of vitiligo  with ruxolitinib  cream . 
Participants who permanently discontinue NB -UVB will be allowed to remain in the study and 
continue to apply ruxolitinib 1.5% cream BID alone. Participants who permanently discontinue 
ruxolitinib 1.5% cream BID will be allowed to remain in the study and con tinue NB -UVB 
phototherapy alone.  
4.2. Overall Study Duration  
The study begins when the first participant signs the study ICF. It is estimated that an individual 
will participate for approximately 14  months (up to 30 days for screening, up to 48 weeks of 
treatment, and 30 days for safety follow -up). 
A participant is considered to have completed the study if they have completed the 48-week 
treatment period and the safety -follow -up period. A study is considered completed when the last 
participant last visit has occurred.  
4.3. Study Termination  
The investigator retains the right to terminate study participation at any time, according to the 
terms specified in the study contract. The investigator is to notify the IRB/IEC of the study's 
completion or early terminatio n in writing, send a copy of the notification to the sponsor or 
sponsor's designee, and retain [ADDRESS_630686] ize the 
scientific integrity of the study, regulatory acceptability, and/or participant safety. Therefore, 
adherence to the criteria as specified in the Protocol is essential. Prospective approval of Protocol 
deviations to recruitment and enrollment criter ia, also known as Protocol waivers or exemptions, 
are not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Ability to comprehend and willingness to sign a written ICF for the s tudy (or by [CONTACT_490539]) . 
2. Age ≥ 12 years at the time of signing the ICF.  
3. A clinical diagnosis of non segmental vitiligo with depi[INVESTIGATOR_490512]:  
a. ≥ 0.5 F -VASI on the face  
b. ≥ 3.0 T-VASI ( body areas not including the face ) 
c. Total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.  
4. Agree to discontinue all agents used to treat vitiligo from screening through the final 
safety follow -up visit. Over -the-counter preparations deemed acceptable by  [CONTACT_427451].  
5. Willingness  to take appropriate contraceptive measures to avoid pregnancy or fathering a 
child for the duration of study participation with the exception of the following:  
a. Female  participant s of nonch ildbearing potential (ie, or surgically sterile with a 
hysterectomy and/or bilateral oophorectomy OR postmenopausal [≥ 12 months of 
amenorrhea without an alternative medical cause ]). 
Note: Permitted methods in preventing pregnancy (see Appendix  A) should be 
communicated to the participants and their understanding confirmed.  
5.2. Exclusion Criteria  
Participants are excluded from the study i f any of the following criteria apply:  
1. No pi[INVESTIGATOR_427424].  
2. Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other 
skin depi[INVESTIGATOR_262807] (eg, pi[INVESTIGATOR_312303], pi[INVESTIGATOR_490513], leprosy, postinflammatory 
hypopi[INVESTIGATOR_371], progressive macule hypomelanosis, nevus anemicus, chemical 
leukoderma, and tinea versicolor).  
3. Used depi[INVESTIGATOR_352901] (eg, monobenzone) for past treatment of vitiligo or other 
pi[INVESTIGATOR_312294].  
Note : Prior use of hydroquinone is not prohibited.  
Incyte Corporation  Version [ADDRESS_630687] 36 phototherapy sessions for vitiligo within 6  months and shown little 
or no re pi[INVESTIGATOR_490514], including NB -UVB and 
excimer laser.  
6. History of thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, 
ischemic stroke, myocardial infarction) . 
7. Concurrent conditions and history of other disea ses: 
a. Any other skin disease that, in the opi[INVESTIGATOR_871], would interfere with 
the study cream application or study assessments.  
b. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes 
zoster, chicken pox) within 1 w eek before baseline.  
c. Conditions at baseline that would interfere with evaluation of vitiligo.  
d. Any serious illness or medical, physical, or psychiatric condition(s) that, in the 
investigator's opi[INVESTIGATOR_1649], would interfere with full participation in the study, i ncluding 
application of study cream and attending required study visits; pose a significant risk 
to the participant; or interfere with interpretation of study data.  
Examples include but are not limited to the following:  
− Clinically significant or uncontroll ed cardiac disease, including unstable angina, 
acute myocardial infarction within 6 months from Day 1 of study cream 
application, [LOCATION_001] Heart Association Class III or IV congestive heart failure, 
and arrhythmia requiring therapy or uncontrolled hyperten sion (blood pressure 
> 150/90 mmHg) unless approved by [CONTACT_7195]/sponsor.  
− Concurrent malignant disease or a history of that in the 5 years preceding the 
baseline visit except for adequately treated nonmetastatic malignancies.  
− Current and/or histo ry of liver disease, including known hepatitis B or C, with 
hepatic or biliary abnormalities.  
− History of tuberculosis.  
− History of alcohol use disorder  or drug addiction within 1 year before screening 
or current alcohol or drug use that, in the opi[INVESTIGATOR_871], will interfere 
with the participant's ability to comply with the application schedule and study 
assessments.  
− Committed to an institut ion by [CONTACT_490540].  
8. Use of any  topi[INVESTIGATOR_490515] (eg, corticosteroids, calcineurin, and 
phosphodiesterase type 4 inhibitors or retinoids) within 1 week  before baseline . 
9. Use of  any of the following treatments within 4 weeks  before baseline:  
a. Melanocyte -stimulating agents (eg, afamelanotide).  
b. Immunomodulating systemic medications (eg, corticosteroids, methotrexate, 
cyclosporine).  
Incyte Corporation  Version 1  Page 28 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  28 c. Any other systemic therapi[INVESTIGATOR_427426]/visible 
light or impact skin pi[INVESTIGATOR_371], for example, tetracyclines, metoxypsoralens.  
d. Received live attenuated vaccine.  
10. Use of laser or any kind of phototherapy (including tanning bed or intentional UV 
exposure) within  12 weeks  before baseline.  
11. Use of  any of the following treatments within 5 half -lives  or 12 weeks  (whichever is 
longer) before baseline:  
a. Biologic agents for the treatment of vitiligo.  
b. Investigational or experimental therapy or procedures for vitiligo.  
Note : Investigational biologics should be discussed with the sponsor to determine 
whether a longer period of discontinuation is required.  
12. Previously received JAK inhibitors, systemic or topi[INVESTIGATOR_2855].  
13. Any of the following clinical laboratory values at screening:  
a. Hem oglobin (< 10 g/dL).  
b. Liver function tests:  
− AST or ALT ≥ 2 × ULN.  
− Alkaline phosphatase and/or bilirubin > 1.5 × ULN (isolated bilirubin 
> 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%).  
c. Severe renal disease (with creatinine  clearance <  30 mL/min) or renal disease 
requiring dialysis.  
d. Clinically significant abnormal TSH or free T4 at screening as determined by [CONTACT_1275].  
e. Positive serology test results at screening for HIV antibody.  
14. Appropriate BMI:  
a. Adults : < 17 or > 40 kg/m2. 
b. Adolescents (age  12 to <  18 years): BMI -for-age in the < 5th percentile or ≥ 85th 
percentile range  according to the CDC BMI Percentile Calculator for Child and Teen 
(CDC ). 
15. Pregnant or lactating, or those considering pregnancy during the period of their study 
participation.  
16. In the opi[INVESTIGATOR_490516].  
17. Known allergy or reaction to any component of the ruxolitinib for mulation.  
18. No venous access outside of the areas to be treated.  
19. Live with anyone participating in any current Incyte -sponsored ruxolitinib cream study.  
20. Employees of the sponsor or investigator or are otherwise dependents of them.  
Incyte Corporation  Version [ADDRESS_630688] been applied to the areas to be treated, participants 
should follow the application guidance (see Section  6.6.1 ). 
Participants should not take baths or showers within [ADDRESS_630689] within 2 hours before and after the study 
cream application.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently enrolled in the study .  
Tests with results that fail eligibility requirements may be repeated once during screening if the 
investigator be lieves that the participant would be eligible if retested. Additionally, a participant 
who fails screening may  repeat the screening process 1  time if the investigator believes that there 
has been a change in eligibility status or any laboratory abnormality  is inconsistent with the 
participant’s medical history. Participants who rescreen must  reconsent and  be assigned a new 
screening number.  
5.5. Replacement of Participants  
Participants will not be replaced during the study.  
6. STUDY TREATMENT  
6.1. Study Treatments Admin istered  
Table  6 and Table  7 present the study treatm ent information. Participants should apply study 
cream only to depi[INVESTIGATOR_490517] a T -BSA 
(facial and nonfacial) of ≤  10% BSA. Participants should continue to treat all depi[INVESTIGATOR_490518].  
On visit days, study cream will be applied in the clinic during the visit. Participants should 
remove study cream from the tube in fingertip units until all of the areas to be treated are covered 
by a thin film; the tube will be weighed before and after ap plication to determine the 
participant’s dosage. On the day of a visit, the participant should not apply the study cream at 
home and will apply study cream from a new kit in the clinic  during the visit  under direct 
supervision of the site staff . Participan ts will be instructed to document the treated areas and be 
advised to limit use to no more than 1 tube ( 60 g) per week. Application instructions will be 
provided by [CONTACT_233528], and the participants will record their daily applications via a 
diary  card given to the participants during each study visit. Refer to the Study Pharmacy Manual 
for participant instructions for handling of study cream.  
On days where there are PK or translational assessments, study cream should be applied after 
these procedu res have occurred.  
Incyte Corporation  Version [ADDRESS_630690] the study site to discuss with the investigator whether additional 
evaluation at the clinic is required. Participants may not treat the expanded or newly identified 
areas with study cream. If any other skin products that are permitted under the study Protocol are 
used, participants should continue these unchanged during the study.  
See Appendix  C for COVID -19-related guidance.  
Table  6: Study Treatment Information (Ruxolitinib Cream)  
Study treatment name:  [CONTACT_490558]:  Cream  
Mechanism of action:  JAK inhibitor  
Unit strength:  1.5%  
Route of administration:  Topi[INVESTIGATOR_490519]:  A thin film is applied BID to depi[INVESTIGATOR_352857].  
Packaging and labeling:  Ruxolitinib cream will be provided in 60 g tube s. Each tube will be 
labeled as required per country requirement.  
Storage:  Ambient (15°C -30°C/59°F -86°F)  
Status of treatment in 
participating countries:  Investigational  
Table  7: Study Treatment Information (NB -UVB)  
Study treatment name:  [INVESTIGATOR_96643]-UVB (311 -312 nm)  
Dosage formulation:  Cleared medical device  
Dosage levels:  Starting dose = 200 mJ/cm2 
Increase dose by 10% at each visit until mild erythema lasting 
< 24 hours as reported by [CONTACT_2299] . 
Hold dose at 15 00 mJ/cm2 – this may vary or be increased over the 
course of treatment. Dose information will be collected in the 
database.  
Administration 
instructions:  Three times a week ; not on consecutive days.  
Status of treatment in 
participating countries:  Standard of care  
Incyte Corporation  Version [ADDRESS_630691] confirm and document that appropriate temperature conditions 
(ruxolitinib cream is to be stored between 15°C and 30°C [59°F -86°F]) have been maintained 
during transit for all study  treatments received and any discrepancies are reported and resolved 
before use of the study cream . 
Only participants enrolled in the study may receive study treatment, and only authorized site 
staff may supply study cream. Immediately after application of  ruxolitinib cream, participants are 
to wash their hands thoroughly with soap and warm water (unless the area to be treated includes 
the hands). Refer to the Study Pharmacy Manual for participant instructions for handling of 
study cream.  
All study cream mu st be stored in a secure, environmentally controlled, and monitored (manual 
or automated) area in accordance with the labeled storage conditions with access limited to the 
investigator and authorized site staff. Participants should store study cream at amb ient 
temperature conditions.  
The investigator (or designee) is responsible for study cream accountability, reconciliation, and 
record maintenance (ie, receipt, reconciliation, and final disposition records). Inventory and 
accountability records must be mai ntained and readily available for inspection by [CONTACT_319853]. The 
investigator or designee must maintain records that document:  
• Delivery of study cream to the study site.  
• Inventory of study cream at the site.  
• Participant use of the study cream , including tube counts from each supply dispensed.  
• Return of study cream to the investigator or designee by [CONTACT_4317].  
The investigational product must be used only in accordance w ith the Protocol. The investigator 
will also maintain records adequately documenting that the participants were provided the 
specified study cream. These records should include dates, quantities, and any available batch or 
serial numbers or unique code num bers assigned to the investigational product and study 
participants.  
Completed accountability records will be archived by [CONTACT_779]. The investigator or designee will 
be expected to collect and retain all used, unused, and partially used containers of study  cream 
until verified by [CONTACT_11200] (unless otherwise agreed to by [CONTACT_456]). At the conclusion 
of the study, the investigator or designee will oversee shipment of any remaining study cream 
back to the sponsor or its designee for destruction acco rding to institutional SOPs. If local 
procedures mandate on -site destruction of investigational supply, the site should (where local 
procedures allow) maintain the investigational supply until the study monitor inspects the 
accountability records in order to evaluate compliance and accuracy of accountability by [CONTACT_198373]. At sites where the study cream is destroyed before monitor inspection, the 
monitors rely on documentation of destruction per the site SOP.  
Further guidance and information for  the final disposition of unused study cream are provided in 
the study materials provided to sites.  
Incyte Corporation  Version 1  Page 32 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  32 6.3. Measures to Minimize Bias : Randomization and Blinding  
Not applicable as this is an open -label study . 
6.4. Study Treatment Compliance  
Compliance with all study -related treatments must be emphasized to the participant by [CONTACT_89184], and appropriate steps should be taken to optimize compliance during the study.  
Compliance with ruxolitinib cream will be evaluated by [CONTACT_4317]' adherence to the application 
regimen and drug accountability documented by [CONTACT_352966]/designee . 
In general, the application compliance will be determined by [CONTACT_352937], which should be within 70% to 13 0% of the prescribed 
number of applications. Participants will be instructed to bring all tubes of study cream with 
them to the study visits in order for site personnel to conduct tube counts to assess study cream 
accountability. The drug accountability do cumentation will be used by [CONTACT_427454].  
Compliance with NB -UVB will be determined by [CONTACT_490541]-UVB machine. Participants will be instructed to bring the session recording device with 
them to the study visits in order for site personnel to conduct the compliance assessment. Site 
staff must provide source documentation of all treatment dates and details.  
6.5. Dose Modifications  
6.5.1.  Criteria and Procedures for Application Interruptions of Study Cream  
Safety concerns should be discussed with the sponsor immediately upon occurrence or awareness 
to determine whether the participant should continue or discontinue application of study cream.  
In some circumstances, it may be necessary to temporarily interrupt application of ruxolitinib 
cream. Except in cases of emergency, it is recommended that any findings of concern (eg, AE) 
be confirmed and that the investigator consult with the sponsor medi cal monitor (or other 
representative of the sponsor) before interrupting study cream. Additionally, the investigator 
must obtain approval from the sponsor before restarting study cream. Participants who have a 
recurrence of the initial AEs upon restarting the study cream and the AE is confirmed related to 
the study cream may need the study cream to be permanently discontinued.  
If a participant has an AE at an application site, application of ruxolitinib cream to that site can 
be temporarily interrupted with out interrupting application of study cream elsewhere.  
Instructions for application interruptions for ruxolitinib cream are outlined in Table  8. Individua l 
decisions regarding interruptions should be made using clinical judgment in consultation with the 
medical monitor (whenever possible), taking into account relatedness of the AE to the study 
cream and the participant's underlying condition.  
If it is uncle ar whether a skin reaction is related to ruxolitinib cream or the NB -UVB, the 
investigator should consider interrupting both.  
Incyte Corporation  Version 1  Page 33 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  33 Table  8: Guidelines for Interruption and Restarting of Study Cream  
Adverse Event  Action Tak en 
Chemistry  
ALT (> 3 × ULN) or AST (> 3 × ULN)  • Laboratory abnormalities should be confirmed with repeat 
testing within 48 hours whenever possible and immediate 
delivery of the laboratory results requested.  
• Study cream applications must be interrupted. At the 
discretion of the investigator, after consultation with the 
sponsor, study cream application may be restored once 
these have resolved.  
Other laboratory abnormalities  
Any other Grade 3 or higher laboratory 
abnormality  • Laboratory abnormalities shoul d be confirmed with repeat 
testing within 48 hours whenever possible and immediate 
delivery of the laboratory results requested.  
• Study cream applications must be interrupted. At the 
discretion of the investigator, after consultation with the 
sponsor, study  cream application may be restored once 
these have resolved.  
Any Grade [ADDRESS_630692] or ALT (> 5 × ULN)  • Laboratory abnormalities should be confirmed with repeat 
testing within 48 hours whenever possible and immediate 
delivery of the laboratory results requested.  
• Discontinue study cream if lab abnormalities are 
confirmed.  
6.5.2.  Criteria for Permanent Discontinuation of Study Cream Due to an Adverse 
Event  
The occurrence of unacceptable severity of an AE that is  related to study cream applica tion will 
require that the study cream be permanently discontinued. Unacceptable severity is defined as 
follows:  
• Occurrence of an AE that is related to treatment with the study cream that, in the 
judgment of the investigator or the sponsor's medical monito r, compromises the 
participant's ability to continue study -specific procedures or continuing treatment is 
considered not to be in the participant's best interest.  
• Worsening of vitiligo that requires treatment with a prohibited concomitant 
medication.  
See Section  [ADDRESS_630693] participant responses  about 
pi[INVESTIGATOR_96225]/tenderness of the skin  during  the previous days. Table  9 shows the dose modifications 
that should occur based on skin reaction. These dose modifications will be programmed into the 
machine.  If there is severe pi[INVESTIGATOR_96225]/redness or there is pain, the participant may need to have an 
unscheduled visit for the invest igator to evaluate the participant . The participant is not to 
Incyte Corporation  Version 1  Page 34 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  34 undergo any further light treatments  until it resolves , and treatment can  restart at a 15% 
decreased dose. Once the ordered holding dose is reached, hold at that dose until evaluated by 
[CONTACT_093]. The holding dose may be increased at that time.  
If it is unclear whether a skin reaction is related to ruxolitinib cream or the NB -UVB, the 
investigator should consider interrupting both.  
If the participant has missed NB -UVB treatment s, dose adju stments for missed treatments are 
listed in  Table  10. 
Table  9: NB-UVB Dose Adjustments Based on the Skin Assessmen ts 
Responses to NB-UVB 
Machine Questiona Skin Assessment  Dose Adjustment  
No, or < [ADDRESS_630694] treatment  Increase by 10%  
24 – 48 hours  Mild erythema but not painful  Hold dose constant  
> 48 hours  Moderate erythema or painful  Decrease by 10%  
Still red/ pain Severe, painful erythema  Wait until resolution, decrease 
dose by 15%  
a The NB -UVB machine will provide the following  question to the participant, "Were you in pain or red after your 
last treatment?". The participant's r esponse will result in a hold or change to the dose as noted in the dose 
adjustment column.  
Table  10: NB-UVB Dose Adjustments for Missed Treatments  
Length of Time Since Previous Dose  Dose Adjustment  
Up to 1 week  Maintain dose  
1-2 weeks  Decrease by 25%  to a minimum of 200 mJ/cm2 
2-3 weeks  Decrease by 50%  to a minimum of 200 mJ/cm2 
3-4 weeks  Decrease by 75%  to a minimum of 200 mJ/cm2 
> 4 weeks  Restart at 200 mJ/cm2 
6.6. Concomitant Medications and Procedures  
All concomitant medications and treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be re corded in the eCRF. Any 
medication or procedure received up to [ADDRESS_630695] application of study cream for treatment of the SAE should be reported until the SAE is no 
longer being followed (see Section  9.3). 
Incyte Corporation  Version [ADDRESS_630696] clinical judg ment with these recommendations and adhere to 
the guidelines as closely as possible. Please consult the sponsor if there are specific questions.  
• Participants may use bland emollients or camouflage makeups.  
Note : Emollients or camouflage makeups should not be used within [ADDRESS_630697] then be washed off and 
the skin dried before application of the study cream.  
• If sunscreen is needed, a mineral -based sunscreen (such as zinc oxide – or titanium 
oxide –based) with SPF of at least 30 is recommended 2 hours after study cream  
applicati on and/or NB-UVB  phototherapy . 
Note : Sunscreen must be removed from the skin before study cream application if it 
has been applied to the areas to be treated.  
• Participants who receive combination therapy should apply ruxolitinib cream at least 
2 hours befo re NB -UVB phototherapy.  
• Concomitant oral vitamins and other skin products should be approved by [CONTACT_427456].  
6.6.2.  Restricted Medications and Measures  
The following are restricted during the study under spec ified conditions:  
• Use of any over -the-counter, nonprescription preparations (including vitamins, 
minerals, and phytotherapeutic, herbal, or plant -derived preparations) within 7 days 
before the baseline visit through the safety follow -up visit, unless deeme d acceptable 
by [CONTACT_093].  
• Use of any prescription medication (including immunizations, phytotherapeutic, 
herbal, or plant -derived preparations) within 7 days before the baseline visit through 
the safety follow -up visit, unless deemed acceptable by [CONTACT_093].  
• Baths or showers within 2 hours after study cream application.  
• Treatment for dermatologic disease besides vitiligo (eg, AD or psoriasis) is allowed 
for areas not being treated for vitiligo , if: 
− It involves < 10% of the BSA outside of the areas treated for vitiligo.  
− Topi[INVESTIGATOR_22777], pi[INVESTIGATOR_031], or corticosteroids Class 6 or 7 (or low potency 
per WHO classification; see  Appendix  C) are at a stable dose.  
− Topi[INVESTIGATOR_427435] 1 through 5 (see  Appendix  C) are used for no longer 
than 7 sequential days and no more than 14 days in total.  
Incyte Corporation  Version 1  Page 36 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  36 • Use of oral corticosteroids for no longer than 7 days if deemed acceptable by [CONTACT_490542] (eg, asthma 
exacerbation, bronchitis).  
6.7. Prohibited Medications and Procedures  
Participants should not use any other treatments for vitiligo at any time during the study. The 
following medications are not permitted during the study:  
• Any investigational medica tion other than the study cream  
• Treatment known to affect the course of vitiligo, such as skin bleaching treatments 
(eg, hydroquinone) or depi[INVESTIGATOR_6164] (eg, monobenzone)  
Note : Skin bleaching (eg, hydroquinone) use is prohibited during the study but is 
allowed as prior therapy.  
• Other topi[INVESTIGATOR_12450] (except those in Section  6.6.1 ) or treatments for vitiligo 
(includ ing corticosteroids [topi[INVESTIGATOR_2855], systemic, or oral], vitamin D derivatives, 
calcineurin inhibitors, laser or surgical treatments, phototherapy, or other procedures).  
• Biological therapi[INVESTIGATOR_490520] a gents  
• Any phototherapy other than that prescribed as part of the study  
• Use of a tanning bed  
• Receipt of a live vaccine during the course of the study and wit hin [ADDRESS_630698]  be discontinued fr om study treatment for the following reasons:  
• The participant becomes pregnant.  
• Consent is withdrawn.  
Note : Consent withdrawn means that the participant has explicitly indicated that they 
do not want to be followed any longer; in this case, no further dat a (except data in 
public domain) may be solicited from or collected regarding the participant. 
Participants may choose to discontinue application of study cream and remain in the 
study to be followed for safety.  
Incyte Corporation  Version 1  Page 37 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  37 • Further participation would be injurious to the participant's health or well -being, in 
the investigator's medical judgment.  
• Any AE of unacceptable severity as noted in Section  6.5.2 . 
• The study is terminated by [CONTACT_456].  
• The study is terminated by [CONTACT_19407], IRB, or IEC.  
A participant may be discontinued from study treatment as follows:  
• A participant is found not to have met eligibility criteria (any exclusion criterion or 
any inclusion criteria related to participant safety) or if legal requirements have been 
violated.  
• If, at 2 consecutive study visits, a participant's study cream usage exceeds 1 tube 
(60 g) per week.  
• If a participant is noncompliant with study procedures or s tudy cream application in 
the investigator's opi[INVESTIGATOR_1649], the medical monitor should be consulted for instruction on 
handling the participant.  
7.1.2.  Discontinuation Procedures  
In the event that the decision is made to permanently discontinue the application of study  cream, 
an EOT visit should be conducted. Reasonable efforts should be made to have the participant 
return for a safety follow -up visit. The last date of the last application of study cream and the 
reason for discontinuation of study cream will be recorded  in the eCRF.  
If a participant is discontinued from study treatment:  
• The study monitor or sponsor must be notified.  
• The reason(s) for withdrawal must be documented in the participant's medical record 
and the primary reason for withdrawal must be included i n the eCRF.  
• The EOT visit should be performed.  
• The date of the EOT visit should be recorded in the eCRF.  
• Participants must be followed for safety until the time of the safety follow -up visit or 
until study cream/treatment –related AEs resolve, return to baseline, or are deemed 
irreversible, whichever is longest.  
If the participant discontinues application of study cream and actively withdraws consent for 
collection of follow -up data (safety follow -up or disease assessment), then no additional data 
collect ion should occur; however, participants will have the option of withdrawing consent for 
study treatment but continuing in the safety follow -up period.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at their own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons.  
Incyte Corporation  Version [ADDRESS_630699] be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_14315]. The participant will be counseled rega rding the importance of 
maintaining the assigned visit schedule and ascertain whether or not the participant 
wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effor t to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant's last known mailing address 
or local equivalent methods). These contact [CONTACT_21457]'s  medical record.  
• Should the participant continue to be unreachable, they will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up. 
Incyte Corporation  Version 1  Page 39 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  39 8. STUDY ASSESSMENTS AN D PROCEDURES  
See Appendix  C for COVID -19-related guidance.  
8.1. Administrative and General Procedures  
8.1.1.  Informed Consent Process  
• The investigator or their representative will explain the nature of the stu dy to the 
participant  or their  legally authorized representative and answer all questions 
regarding the study.  
− Informed consent must be obtained before any study -related procedures are 
conducted, unless otherwise specified by [CONTACT_89191].  
Note : Adolescent participants who bec ome legal adults during the study will be 
asked for their signed consent to continue the study, and in the event of lack 
thereof, will be discontinued from further participation.  
− Informed consent must be obtained using the IRB/IEC -approved version in a 
language that is native and understandable to the participant. A template will be 
provided by [CONTACT_3552]. The sponsor or its designee must review 
and acknowledge the site -specific changes to the ICF template. The ICF must 
include a statement that the sponsor or its designee and regulatory authorities have 
direct access to participant records.  
− The ICF must contain all required elements and describe the nature, scope, and 
possible consequences of the study in a form understandable to the study 
participant.  
• Participants must be informed that their participation is voluntary. Participants or 
their legally authorized representative will be required to sign a statement of informed 
consent that meets the applicable requirements and regulations for the  countries in 
which the study is being conducted as well as the IRB/IEC or study center.  
• The participant must be informed that their personal study -related data will be used 
by [CONTACT_89192]. The level of disclos ure 
must also be explained to the participant.  
• The participant must be informed that their medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by  [CONTACT_9326].  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
• Participants must provide consent to the most current version of the ICF during their 
participation in the study.  
Incyte Corporation  Version 1  Page 40 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  40 • A copy of the ICF(s) must be provided to the participant or the participant's legally 
authorized representative.  
8.1.2.  Screening Procedures  
Screening is the interval between signing the ICF and the day that the participant is assigned to 
the study cream (Day 1). Screening assessments for determination of eligibility may be 
performed over a period lasting up  to 30 days.  
Procedures conducted as part of the participant's routine clinical management (eg, clinical 
laboratory tests) and collected before informed consent is obtained may be used for screening or 
baseline purposes, provided the procedure meets the Pr otocol -defined criteria and has been 
performed within [ADDRESS_630700] the IRT system to obtain the participant ID number during 
screening. Upon determining that the participant is eligible for study entry, the IRT system will 
be contact[CONTACT_490543]. Additionally, the IRT system will be 
contact[CONTACT_490544]. Additional details are 
provided in the IRT Manual.  
8.1.4.  Distribution of Study Reminder Cards and Diaries  
Starting at the Day 1 visit and each visit thereafter, a study cream –specific diary will be given to 
each participant in order to record use of the study cream. The completed diary will be collected 
during each of the participant's visits.  
Qualified clinical site staff will review the participants' entries for compliance. P articipants who 
are noncompliant with their study cream schedule (defined as < 70% or > 130% of the expected 
number of applications between study visits) will have their application instructions reinforced 
by [CONTACT_1720] a qualified designee. Parti cipants will be considered compliant with the 
treatment regimen if they apply at least 70% but no more than 130% of the expected applications 
during participation in the treatment period of the study.  
Participants will be provided with a reminder card star ting on Day 1 and at all visits (through 
Week 48 ). The reminder card will indicate the date/time of the next visit and will also remind the 
participant that they should have their application at the clinic during the visit under site 
supervision after thei r blood draws for PK and safety evaluations have been completed.  
Incyte Corporation  Version 1  Page 41 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  41 8.1.5.  Demography and Medical History  
[IP_ADDRESS].  Demographics and General Medical History  
Demographic data and general medical history will be collected at screening by [CONTACT_490545] a nd will include year of birth/age, race, ethnicity, medical and surgical 
history, and current illnesses. Medical history will include relevant medical or surgical treatment 
within the last 2 years that are considered to be clinically significant by [CONTACT_74169].  
[IP_ADDRESS].  Disease Characteristics and Treatment History  
Vitiligo medical and treatment history, including date of diagnosis, relevant disease 
characteristics, and prior treatments, including systemic treatments, phototherapy, and surgical 
procedures, will  be recorded. Medical history of other conditions related to vitiligo will also be 
collected at screening.  
8.2. Efficacy Assessments  
8.2.1.  Body Surface Area  
Total BSA (includes facial and nonfacial areas) depi[INVESTIGATOR_490521]. Body surface area assessment will be performed by [CONTACT_352942]. The BSA should 
be estimated to the nearest 0.1%. The approximate size of the parti cipant’s entire palmar surface 
(ie, the palm plus 5 digits) should be considered as 1% BSA, and the approximate size of the 
participant’s thumb should be considered as 0.1% BSA.  
Facial BSA (F -BSA) takes into account the facial depi[INVESTIGATOR_490522] a percen tage of the total 
body area.  
Total BSA (T -BSA) takes into account the depi[INVESTIGATOR_490523]: head/neck (including scalp), upper extremities (including axillae), hands, trunk 
(including genitalia), lower extremities (inclu ding buttocks), and feet . 
F-BSA and T -BSA will be assessed at visits listed in Table  3 and Table  4. 
8.2.2.  Vitiligo Area Scoring Index  
Areas affected by [CONTACT_61911][INVESTIGATOR_352863]  
(Hamzavi  et al 2004 ). It is based on a composite estimate of  the overall area of vitiligo patches at 
baseline and the degree of macular repi[INVESTIGATOR_312316].  Facial VASI 
is measured by [CONTACT_352943] (%BSA) and the degree of depi[INVESTIGATOR_371]. 
The %BSA (hand unit) vitiligo involvement is estimated by [CONTACT_490546] (see Section  8.2.1 ). Hand unit is based on participant’s hand size. The i nvestigator uses 
their hand to mimic the participant’s hand size to evaluate %BSA vitiligo involvement. The 
degree of depi[INVESTIGATOR_490524] : 0, 10%, 25%, 50 %, 75%, 90%, or 100%. At 100% 
depi[INVESTIGATOR_371], no pi[INVESTIGATOR_352865]; at 90%, specks of pi[INVESTIGATOR_352866]; at 75%, the 
depi[INVESTIGATOR_352867]; at 50%, the depi[INVESTIGATOR_490525]; at 25%, the pi[INVESTIGATOR_490526] e depi[INVESTIGATOR_312320]; at 10%, only specks of 
depi[INVESTIGATOR_352871]. The F -VASI is then derived by [CONTACT_490547] 1  Page 42 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  42 the vitiligo involvement by [CONTACT_490548] (possible range 0 -3). 
The area " face" is defined as including the area on the forehead to the original hairline, on the 
cheek to the jawline vertically , and laterally from the corner of the mouth to the tragus. The area 
"face" will not include surface area of the lips, scalp, ears, or neck but will include the nose and 
eyelids.  
Total body VASI is calculated using a formula that includes contributions from all body regions 
(possible range,  0-100) as follows:  
 
The body is divided into the following 6 separate and mutually exclusive sites : (1) head/neck, 
(2) hands, (3) upper extremities (excluding hands), (4) trunk, (5) lower extremities (excluding 
feet), and (6) feet. The percentage of vitiligo involvement is estimated in hand units (%BSA) by 
[CONTACT_312357]. Hand unit is based on participant’s 
hand size. The investigator uses their hand to mimic the partic ipant’s hand size to evaluate 
%BSA vitiligo involvement. The degree of depi[INVESTIGATOR_490527] h body site is determined and 
estimated to the nearest of the following percentages : 0, 10%, 25%, 50%, 75%, 90%, or 100%. 
The T -VASI is then derived by [CONTACT_490549].  
F-VASI and T -VASI will be assessed at visits listed in Table  [ADDRESS_630701] of these assessments will be provided in the Study Manual.  
  
 
  
 
  

Incyte Corporation  Version 1  Page 43 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  43   
 
.  
 
8.2.5.  Photography  
Photography of the face and/or body areas affected with vitiligo will be obtained at visits listed 
in Table  3 and Table  4. 
All sites will use 2 -dimensional photography to photograph areas of the parti cipant’s face 
affected with vitiligo and 2 target nonfacial depi[INVESTIGATOR_312294].  
Target nonfacial vitiligo depi[INVESTIGATOR_352881] : At the screening  visit, depi[INVESTIGATOR_490528]'s overall disease will be s elected as 
targeted nonfacial vitiligo depi[INVESTIGATOR_312294]. These areas will be assessed, measured, and 
documented in the participant's medical record at each subsequent visit during the study (see  
Table  3 and Table  4). A note should be made in their medical record, and the baseline 
photographs can be marked with the location of the target -depi[INVESTIGATOR_312320]. The genitalia area 
should not be photographed.  
If photo quality at screening is not adequate, the photography may be repeated on Day 1.  The 
baseline photos are defined as the adequate ones eit her taken at screening or Day 1.  
Ad hoc photography of skin -related AEs is recommended.  
Photographic procedures will be standardized, and a full description of the methodology will be 
provided in a photography manual to be provided to the sites.  
  
 
 
 
 
 
 

Incyte Corporation  Version [ADDRESS_630702] application of study cream. Adverse events for enrolled participants that 
begin or worsen after informed consent should be re corded on the Adverse Event Form in the 
eCRF regardless of the assumption of a causal relationship with the study cream. Conditions that 
were already present at the time of informed consent should be recorded on the Medical History 
Form in the eCRF. Advers e events (including laboratory abnormalities that constitute AEs) 
should be described using a diagnosis whenever possible rather than by [CONTACT_490550].  
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorized representative). The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and r emain responsible f or following up on AEs that are serious, 
considered related to the study cream/procedures, or that caused the participant to discontinue the 
study cream  or NB -UVB . Care will be taken not to introduce bias when detecting AEs and/or 
SAEs. Open ended and nonl eading verbal questioning of the participant, such as "How are you 
feeling?" , is the preferred method to inquire about AE  occurrences. Adverse events may also be 
detected when they are volunteered by [CONTACT_312360], laboratory tests, or other assessments. The definition, 
reporting, and recording requirements for AEs are described in Section  9. 
All SAEs will be reported to the sponsor or designee within 24 hours. The investigator will 
submit any updated SAE data to the sponsor within 24 hours of it being available.  
After the initial AE/SAE report, the investigator is required  to proactively follow each participant 
at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
8.3.2.  Physical Examinations  
Physical examinations will be conducted at the timepoints listed in Table  3 and Table  4. 
A comprehensive physical examination will include height and body weight and assessment of 
the following organ or body systems : skin; head, eyes, ears, nose, and throat; thyroid; lungs; 
cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes. A brief 
neurologic examination will also be performed.  

Incyte Corporation  Version [ADDRESS_630703] be performed by a medically qualified individual such as a licensed 
physician, a physician's assistant, or an advanced registered nurse practitioner, as local law 
permits.  
8.3.3.  Vital Signs  
Vital sign measurements will be conducted at the timepoints listed in Table  [ADDRESS_630704]. Any abnormalities that are considered clinically 
significant in the judgment of the investigator are  to be reported as AEs.  
8.3.4.  Electrocardiograms  
Electrocardiograms will be performed at screening or if deemed clinically necessary . 
A single 12 -lead ECG will be obtained at screening (12 -lead ECG performed within 2 months 
before baseline is acceptable) using a n ECG machine that automatically calculates the heart rate 
and measures PR, QRS, QT, and QTc intervals. All [ADDRESS_630705].  
The decision to include or exc lude a participant or withdraw a participant from the study 
treatment based on an ECG flagged as "Abnormal, Clinically Significant" is the responsibility of 
the investigator, in consultation with the sponsor's medical monitor, as appropriate. Clinically 
notable abnormalities that are considered clinically significant in the judgment of the investigator 
are to be reported as AEs.  
8.3.5.  Laboratory Assessments  
Required laboratory tests are listed in Table  13. See Table  3 and Table  4 for timing of 
assessments . Clinical laboratory tests will be performed at a central laboratory (refer to the 
Laboratory Manual for sample handling and shippi[INVESTIGATOR_3931]).  
Clinically signif icant abnormal laboratory findings are those that induce clinical signs or 
symptoms, require concomitant therapy, or require changes in study cream or NB -UVB.  All 
laboratory tests with values considered clinically significantly abnormal during participatio n in 
the study, or within [ADDRESS_630706] application of study cream, should be repeated until the 
values return to normal or baseline or are no longer considered clinically significant by [CONTACT_63200].  
See Section  9.1 for information regarding laboratory abnormalities that should be recorded as an 
AE in the eCRF.  
Incyte Corporation  Version 1  Page 48 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  48 Table  13: Required Lab oratory Analytes  
Serum Chemistriesa Hematology  Urinalysis  Serology  Other  
Albumin  
Alkaline phosphatase  
ALT  
AST  
Bicarbonate  
Blood urea nitrogen  
Calcium  
Chloride  
Creatine kinase  
Creatinine  
Glucose  
Lactate dehydrogenase  
Phosphate  
Potassium  
Sodium  
Total bilirubin  
Direct bilirubin (if total 
bilirubin is elevated 
above ULN)  
Total protein  Complete blood count, 
including:  
• Hemoglobin  
• Hematocrit  
• Mean corpuscular 
volume (MCV)  
• Platelet count  
• Mean platelet volume  
• Red blood cell count  
• Reticulocyte count  
• White blood cell count  
 
Differential count, 
including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  Color and 
appearance  
pH and specific 
gravity  
Bilirubin  
Glucose  
Ketones  
Leukocytes  
Nitrite  
Occult blood  
Protein  
Note: Abnormal 
results should be 
microscopi[INVESTIGATOR_490529].  HIV antibody  FSHb 
Free T4  
TSH  
Vitamin D2 and 
D3 
Pregnancy Testing  
Female participants of childbearing potential will 
undergo a  serum test at  the screening and safety 
follow -up visits. A urine test will be conducted at all 
other visits. A positive urine test will be confirmed by a 
serum test.  
Note : Additional tests may be required, as agreed by [CONTACT_147100], based on emerging safety data or to rule out a 
diagnosis.  
a All serum chemistries will be performed on samples collected without respect to food intake (ie, nonfasting).  
b FSH is only measured for postmenopausal women (defined by [CONTACT_78494] ≥ 12 months without an alternative medical 
cause before screening); FSH should be in the postmenopausal range to consider the participant of nonchildbeari ng potential.  
Incyte Corporation  Version 1  Page 49 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  49 [IP_ADDRESS].  Pregnancy Testing  
A serum pregnancy test will be required for all women of childbearing potential during screening 
and at the safety follow -up visit (30 [+ 7] days after EOT). Urine pregnancy tests will be 
conducted as outlined in Table  [ADDRESS_630707] was positive, the investigator will assess 
the potential benefit/risk to the participant and determine whether it is in the participant's best 
interest to resume study cream and continue participation in the study.  
If a pregnancy is confirmed by  a serum pregnancy test, see Section  9.7 for reporting 
requirements.  
[IP_ADDRESS].  Serology  
An HIV antibody assessment will be performed at the screening visit to rule out infection 
(see Table  3). Serology tests should be performed early in the screening process due to the length 
of time needed to obtain the results . Additional tests may be performed if clinically indicated.  
8.4. Pharmacokinetic Assessments  
Venous blood samples will be collected as indicated in Table  [ADDRESS_630708] application of 
study cream before the blood draw (if applicable) will be recorded in the eCRF.  
Instructions for sample preparation and shippi[INVESTIGATOR_352884]. 
Participants will receive reminder cards in advance of the study visit providing instruction to 
hold the application of study cream on the day of the visit and a place to record the time of the 
prior application of study cream.  
Pharmacokinetic blood samples can be collected before application of study cream  during study 
visits noted in the Table  [ADDRESS_630709] adequately document this in the eCRF and not take the PK blood sample for 
that visit. After the PK sample is drawn, participants will apply ruxolitinib cream 1.5% at the 
site. 
All analyses will be conducted by [CONTACT_109912] (Wilmington, DE) or Incyte's designee.  
  
 
 
 
 
 

Incyte Corporation  Version 1  Page 50 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  50  
 
8.6. Unscheduled Visits  
Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical 
and laboratory tests may be performed, as clinically indicated.  
8.7. End of Treatment and/or Early Termination  
If a deci sion is made that the participant will permanently discontinue application of study 
cream, the EOT visit should be conducted. If the EOT visit coincides with a regular study visit, 
then the EOT evaluations will supersede those of that scheduled visit, and the data should be 
entered in the EOT page in the eCRF. If this decision does not coincide with a regular visit, 
reasonable efforts should be made to have the participant return to the site to have the EOT 
procedures completed.  
8.8. Safety Follow -Up 
The safety follow -up period is the interval between the EOT visit and the scheduled safety 
follow -up visit, which should occur 30  (+ 7) days after the EOT visit (or after the last application 
of study cream if an EOT visit was not performed).  
Adverse events and SAEs must be reported up until at least [ADDRESS_630710] application of 
study cream/treatment . Adverse events and SAEs must be followed  until toxicities resolve, return 
to baseline, or are deemed irreversible. Reasonable efforts should be made to have the  participant 
return for the safety follow -up visit and report any AEs that may occur during this period.  

Incyte Corporation  Version 1  Page 51 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  51 9. ADVERSE EVENTS : DEFINITIONS AND PROC EDURES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  
9.1. Definition of Adverse Event  
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or 
not it is considered drug -related.  
• An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new  or exacerbated) temporally associated with the use of study 
cream.  
Additional Guidance for Events Meeting the Adverse Event Definition  
• Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from 
baseline, considered clin ically significant in the medical and scientific judgment of the investigator 
(ie, not related to progression of underlying disease) are to be reported as an AE.  
• Abnormal laboratory test results are to be reported as an AE if they are considered clinically  
meaningful, induce clinical signs or symptoms, require concomitant therapy, or require changes in 
study cream. Whenever possible, a diagnosis (eg, anemia, thrombocytopenia) should be recorded in 
the eCRF rather than the abnormal laboratory test result (eg , low hemoglobin , platelet count 
decreased).  
• Exacerbation of a chronic or intermittent pre -existing condition/disease, including either an increase 
in the frequency and/or intensity of the condition, is to be reported as an AE.  
• New conditions detected or d iagnosed after the start of study cream application are to be reported as 
an AE.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction are to be reported as 
an AE.  
• Signs and/or symptoms from application errors of a study cream (eg,  overdose) or a concomitant 
medication are to be reported as an AE.  
• "Lack of efficacy," "disease progression," or "failure of expected pharmacological action" will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments . 
• A condition that leads to a medical or surgical procedure (eg, endoscopy, appendectomy) will be 
reported as an AE if it occurs after obtaining informed consent. The procedure should also be 
reported in the eCRF. If the condition was present before entering the study, then it should be 
captured as medical history.  
• Pre-existing diseases or conditions with expected fluctuations in signs or symptoms should be 
reported as an AE only if the investigator judges the fluctuation to have worsened more than 
expected during study participation.  
9.2. Definition of Serious Adverse Event  
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death  due 
to progression of disease).  
Incyte Corporation  Version [ADDRESS_630711] medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term "life -threatening" in the definition of "serious" refers to an adverse drug experience  that 
places the participant, in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse 
experience as it occurs. This does not include an adverse drug experience that, had it occurred in a 
more severe form, might have caused death . 
c. Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate in the physician's office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_479381], 
the event is serious. When in doubt as to whether hospi[INVESTIGATOR_51956], the AE 
should be considered serious.  
Hospi[INVESTIGATOR_312323] (eg, stent replacement, hip surgery) is not 
considered an SAE.  
Hospi[INVESTIGATOR_312324] 
(ie, elective procedures or routine medical visits) are not considered SAE s. 
d. Results in persistent or significant disability/incapacity  
• The term  "disability" means a substantial disruption of a person's ability to conduct normal life 
functions. This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, and accidental 
trauma (eg,  sprained ankle), that may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is an important medical event  
An important medical event is an event that may not result in death, be immediately life -threatening, or 
require hospi[INVESTIGATOR_49200], based on appropriate medical judgment, 
the event may jeopardize the participant and may require medical or surgi cal intervention to prevent 
one of the outcomes listed in the above definition. Examples of such events include new invasive or 
malignant cancers , intensive treatment in an emergency department or at home for allergic 
bronchospasm, blood dyscrasias, or con vulsions that d o not result in hospi[INVESTIGATOR_059],  or development of 
drug dependency or drug abuse. Secondary malignancies should always be considered SAEs.  
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse 
Events  
Adverse Event and Serious Adv erse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event Form in the eCRF. AEs/SAEs should be reported for enrolled participants, but only 
SAEs need to be reported for screen failure participants. For enrolled participants, conditions that 
were present at the time informed consent was given should be recorded on the Medical History 
Form in the eCRF. For detailed information, refer to the eCRF guidelines.  
Incyte Corporation  Version 1  Page 53 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  53 • When an AE/SAE occurs, it is th e responsibility of the investigator to review all documentation 
(eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic reports) related to the event.  
• The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]'s medical records 
in lieu of completing the Adverse Event Form in the eCRF.  
• There may be rare instances when copi[INVESTIGATOR_63475]. In this 
case, all participant identifiers, with the exception of the participant number, will be redacted by [CONTACT_312366][INVESTIGATOR_205886] . These records can be submitted to 
Incyte Pharmacovigilance by [CONTACT_6968]/fax per the conta ct information listed in the Study Reference 
Manual or as per SAE completing guidelines.  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will 
be documented as the AE/SAE. When a clear diagnosis cannot be identified, each sign or symptom 
should be reported as a separate AE/SAE.  
To the extent possible, each AE/SAE should be evaluated to determine the following:  
• The severity grade (CTCAE v5.0 Grade 1 to 5). See below for further instructions on the assessment 
of intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study cream : suspected 
(yes) or not suspected (no). See below for further instructions on the assessment of causality.  
• The start and end dates, unless unresolved at the final safety follow -up visit.  
• The action taken with regard to study cream as a result of the AE/SAE(s).  
• The event outcome (eg, not recovered/not reso lved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
• The seriousness, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event. Note : If an AE is treated with a concomitant medication or 
nondrug therapy, this action should be recorded on the Adverse Event Form , and the treatm ent 
should be specified on the appropriate eCRF (eg, Prior/Conc omitant Medications, Procedures  and 
Non-Drug Therapy).  
Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1 through 5. If an event is not 
classified by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the 
grade of severity.  
The investigator will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Grade 1 : Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment 
not indicated.  
• Grade 2 : Moderate; minimal, local, or noninvasive treatment indicated; limiting age -appropriate 
activities of daily living.  
• Grade 3 : Severe or  medically significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care activities of daily living.  
• Grade 4 : Life-threatening consequences; urgent treatment indicated.  
• Grade 5 : Fatal.  
Incyte Corporation  Version 1  Page 54 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  54 Assessment of Causality  
• The investigator is obligated to assess the relationship between study cream and each occurrence of 
each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are medical facts, evidence, and/or 
arguments to suggest a causal relationship, rather than that a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the possibility of a relationship.  
• The investigator will also consult the RSI in the IB or Product Inf ormation for ruxolitinib cream, or 
marketed products, respectively, in making their assessment.  
• Alternative causes, such as underlying or concurrent disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study cream application, will be 
considered and investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that they has reviewed the 
AE/SAE and has provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report. However, the causality assessment is one of the criteria 
used when determining regulatory reporting requirements. Therefore , it is very important that 
the investigator always make an assessment of causality based on the available information 
for every event before the initial transmission of the SAE.  
− The investigator may change their opi[INVESTIGATOR_9242] -up information and 
submit the updated causality assessment.  
Incyte Corporation  Version 1  Page 55 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  55 Follow -Up of Adverse Events and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_89207]/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests 
or investigations, histopathological examinations, or cons ultation with other health care 
professionals.  
• Once an AE is detected, it should be followed in the AE eCRFs until it has resolved or until it is 
judged to be permanent; assessment should be made at each visit (or more frequently if necessary) of 
any chang es in severity, the suspected relationship to the study cream, the interventions required to 
treat the event, and the outcome.  
• When the severity of an AE changes over time for a reporting period (eg, between visits), each 
change in severity will be reporte d as a separate AE.  
• If a participant dies during participation in the study or during a recognized follow -up period, the 
investigator will provide the sponsor with a copy of any postmortem findings, including 
histopathology.  
• Updated SAE information will be  recorded in the originally completed eCRF and reported to Incyte 
Pharmacovigilance (via the AE and SAE eCRFs in the EDC) until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up. 
• Any updated SAE data (incl uding SAEs being downgraded to nonserious) will be submitted to the 
sponsor (or designee) within 24  hours of receipt of the information.  
9.4. Reporting of Serious Adverse Events  
Regardless of suspected causality (eg, relationship to study cream, study procedures), all SAEs 
occurring after the participant has signed the ICF through the last safety visit or at least [ADDRESS_630712] be reported to the sponsor (or designee) 
immediately, without undue delay , but not lat er than within 24 hours  of obtaining knowledge of 
its occurrence unless otherwise specified by [CONTACT_89191]. The investigator will submit any 
updated SAE data to the sponsor (or designee) immediately, without undue delay , but not later 
than within [ADDRESS_630713] notify the sponsor (or 
designee) within 24  hours of becoming aware of the event.  
After the initial AE/SAE report, the investigator  is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs  will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
Prompt notification by [CONTACT_490551] a study 
cream under clinical investigation are met.  
If the SAE is not documented in the RSI of the IB for the study cream (new occurrence) and is 
thought to be related to the study cream, the spo nsor or its designee may urgently require further 
information from the investigator for expedited reporting to health authorities. The sponsor or its 
Incyte Corporation  Version 1  Page 56 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  56 designee may need to issue an Investigator Notification to inform all investigators involved in 
any study with the same drug that this SAE has been reported. Suspected unexpected serious 
adverse reactions will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulat ory requirements 
in participating countries.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study cream under clinical investigation. The sponsor 
will comply with cou ntry-specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC , and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions  
according to local regulatory requir ements and sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB and will not ify the IRB/IEC, if appropriate  according to local requirements.  
Serious Adverse Event Reporting  
• Information about all SAEs is collected and recorded on the Adverse Event Form in the eCRF.  
• The investigator must report  within 24 hours of learning of its occurrence any SAE via the EDC 
system (primary method) or by [CONTACT_312369] (only 
if the EDC system is not available). The contact [CONTACT_312370]/fax is listed in the Study Reference Manual or as per the Incyte Reference Guide for 
Completing the Serious Adverse Event Report Form.  
• In circumstances where the EDC system is not accessible for reporting SAE information (initial 
and/or follow -up SAE  information) to the sponsor within [ADDRESS_630714] be kept at the study site (refer to the Incyte Reference Guide for 
Completing the Serious Adverse Event Report Form or St udy Reference Manual for details and for 
the email address or fax number).  
• Follow -up information is also recorded in the eCRF and transmitted to Incyte Pharmacovigilance via 
the EDC system. The follow -up report should include information that was not provi ded previously, 
such as the outcome of the event, treatment provided, action taken with study cream because of the 
SAE (eg, application amount reduced, interrupted, or discontinued), or participant disposition 
(eg, continued or withdrew from study particip ation). Each recurrence, complication, or progression 
of the original event should be reported as follow -up to that event, regardless of when it occurs.  
9.5. Events of Clinical Interest  
Not applicable.  
9.6. Emergency Unblinding of Treatment Assignment  
Not applicable.  
Incyte Corporation  Version [ADDRESS_630715] interfered with the effectiveness of a contraceptive medication or method. When 
a pregnancy has been confirmed in a particip ant during maternal or paternal exposure to study 
cream, the following procedures should be followed in order to ensure safety:  
• The study cream must be discontinued immediately (female participants only).  
• The investigator must complete and submit the Incyt e Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy.  
Data on fetal outcome are collected for regulatory reporting and drug safety evaluation. 
Follow -up should be conducted for each pregnancy to determine outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by [CONTACT_89210]-baby [CONTACT_765]. Pre gnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by [CONTACT_89211]. Pregnancy follow -up information should be 
recorded on the same form and should include an assessment of the possible causal relati onship 
to the sponsor's study cream to any pregnancy outcome, as well as follow -up to the first well -
baby [CONTACT_89212], whichever is later. Refer to the Incyte 
Reference Guide for Completing the Clinical Trial Pregna ncy Form or Study Reference Manual.  
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event Report Form and submitted to the sponsor or its designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fet al death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and 
must be reported as described in Section  9.4 . If an abnormal pregnancy outcome is reported in a 
study participant's partner, the event should be reported to the sponsor on the Clinical Trial 
Pregnancy Form.  
9.8. Warnings and Precautions  
Special warnings or precautions for the stud y cream, derived from safety information collected 
by [CONTACT_3552], are presented in the IB. Additional safety information collected 
between IB updates will be communicated in the form of Investigator Notifications. Any  
important new safety information should be discussed with the participant during the study as 
necessary. If new significant risks are identified, they will be added to the ICF.  
9.9. Product Complaints  
The sponsor collects product complaints on study cream and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and facilitate 
process and product improvements.  
All product complaints associated with material packaged, labeled, and released by [CONTACT_490552]. All product complaints associated with other 
study material will be reported directly to the respective manufacturer.  
Incyte Corporation  Version [ADDRESS_630716] between the 
2 treatment groups, and the sample size is not based on statistical power calculations. The sample 
size is considered to be sufficient to obtain adequate efficacy, safety, tolerability, and PK data to 
achieve the objectives of the study.  
10.2. Populations for Analysis  
Table  14 presents the populations for analysis.  
Table  14: Populations for Analysis  
Populat ion Description  
FAS The FAS includes all participants enrolled in the study who applied study cream 
at least once. The FAS will be used for the summary of demographics, baseline 
characteristics, participant disposition, and analyses of all efficacy and sa fety 
data.  
PK evaluable  The PK evaluable population includes participants who applied study cream at 
least on ce and provided at least [ADDRESS_630717] will review data listings 
of participant application and sample records to identify participants to be 
excluded from the analysis.  
10.3. Level of Significance  
This is an exploratory study, and no formal statistical tests will be performed. All confidence 
intervals will be 95% . 
10.4. Statistical Analyses  
The Statistical Analysis Plan will be developed and finalized before database lock and will 
describe the details of the statistical analyses and proce dures for accounting for missing data. 
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints.  
Incyte Corporation  Version 1  Page 60 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  60 10.4.1.  Efficacy Analysis  
All efficacy assessments will be summarized using descriptive statistics at each visit for FAS.  
[IP_ADDRESS].  Analysis of Primary Efficacy Analysis  
The primary efficacy endpoint is the change from baseline in T -VASI at Week [ADDRESS_630718] deviation, 
minimum, maximum, and the 95% con fidence interval.  
[IP_ADDRESS].  Analysis of Secondary Efficacy Endpoints  
[IP_ADDRESS].1.  Continuous Efficacy Endpoints  
By-visit summary statistics for the following continuous measurements, including actual 
measurement, change from baseline, and percentage change from baseline, will be  presented:  
• F-VASI/T -VASI  
• F-BSA/T -BSA  
Summary statistics, including sample size, mean, median, standard deviation, minimum, 
maximum, first quartile, third quartile, and 95% CI, will be presented by [CONTACT_41995].  
[IP_ADDRESS].2.  Categorical Efficacy Endpoints  
For the foll owing c ategorical parameters, summary statistics will include sample size, frequency, 
percentages and standard error of percentage, and the 95% confidence interval at each visit.  
• Proportion of participants achieving F -VASI50/75/90  
• Proportion of participants achie ving T -VASI50/75/90  
10.4.2.  Safety Analysis  
Safety is being evaluated as a secondary objective in this study. Safety analyses will be 
conducted using the safety population and are summarized in Table  15. 
Incyte Corporation  Version 1  Page 61 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  61 Table  15: Safety Analyses  
Endpoint  Statistical Analysis Methods  
Secondary  Adverse Events  
A TEAE is any AE either reported for the first time or worsening of a pre -existing 
event after first application of study cream. Analysis of AEs will be limited to 
TEAEs, but data listings will include all AEs regardless of their timing to study 
cream application. Adverse events will be coded using MedDRA and tabulated by 
[CONTACT_82523]. Severity of AEs will be based on the 
CTCAE  v5.[ADDRESS_630719] postbaseline value using CTCAE grade will be 
tabulated.  
Vital Signs  
Descriptive statistics and mean change from baseline  will be determined for vital 
signs (blood pressure, pulse, respi[INVESTIGATOR_697], and body temperature) at each 
assessment time.  
10.4.3.  Other Analyses  
Pharmacokinetic endpoints are listed in Section  8.4. Pharmacokinetic analyses will be performed 
using the PK evaluable population. The INCB018424 plasma concentration data will be analyzed 
by [CONTACT_490553].  
Translational endpoints are listed in Section  8.5. Details of translational analyses will be 
provided in the Statistical Analysis Plan.  
10.5. Interim Analysis  
No formal i nterim analysis is planned in this study.  
Incyte Corporation  Version 1  Page 62 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  62 11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol, Protocol amendments, ICF, IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by  [CONTACT_31846]/IEC and Health Authorities, before the study is 
initiated.  
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_490554], the 
policies and procedures established by [CONTACT_1201]/IEC, and institutional requirements.  
• Any amendments to the Protocol will require approval from both Health Authorities 
and IRB/IEC before implementation of changes made to the study d esign, except for 
changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accorda nce with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC.  
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures.  
− Providing oversight of the conduct of the study at the site and adherence to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country -specific regulations.  
• Adhering to the Protocol as described in this document and agreeing that changes to 
the Protocol procedures, with the exception of medical emerg encies, must be 
discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC. Each investigator is responsible for enrolling participants who have met the 
specified eligibility criteria.  
• Retaining records in accordance with all  local, national, and regulatory laws but for a 
minimum period of at least [ADDRESS_630720] article for 
investigation to ensure the availability of study documentation should it become 
necessary for the sponsor or a regulatory authority to review.  
− The investigator must not destroy any records associated wit h the study without 
receiving approval from the sponsor. The investigator must notify the sponsor or 
its designee in the event of accidental loss or destruction of any study records. If 
the investigator leaves the institution where the study was conducted,  the sponsor 
or its designee must be contact[CONTACT_89224].  
Incyte Corporation  Version 1  Page 63 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  63 − All eCRF data entered by [CONTACT_779] (including audit trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the site in compliance with applicable record retention regulations. 
The sponsor will retain the original eCRF data and audit trail.  
11.1.1.  Identification of the Coordinating Principal Investigator  
A coordinating principal investigator [INVESTIGATOR_490530]. As part of his or her responsibilities, the coordinating principal investigator [INVESTIGATOR_490531]. Agreement with the final CSR will be documented by [CONTACT_312374].  
11.2. Data Management  
Data management will be performed in a validated EDC system. The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion guidelines for instructions on data entry in the 
eCRF. The study monitor will reference the Monitoring Plan in order to ensure that each issue 
identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan's r equirements. Other data outside the EDC system required in the study conduct of 
the Protocol such as documents or results transmitted to the sponsor via a central laboratory or 
specialized technical vendors and, as designated by [CONTACT_456], will have thei r own data flow 
management plans, study charters, or , as applicable.  
The sponsor (or designee) will be responsible for:  
• Managing the integrity of the data and the quality of the conduct of the study, such as 
ensuring that study monitors per form ongoing source data verification to confirm that 
data entered into the eCRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study i s being conducted in accordance with the currently 
approved Protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
• Managing and reconciling the data generated, and/or collected including documents 
and results such as laboratory or imaging data analyzed centrally by a designated 
vendor of the sponsor.  
The investigator will be responsible for:  
• Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
• Delivering, or ensuring the deliver y of, all other results, documents, data, know -how, 
or formulas relating to the study to the sponsor or designee electronically and/or 
centrally (eg, laboratory data, imaging data, , photographs, diary data), 
or as otherwise specified in the Protocol.  
• Maintaining adequate and accurate source documents and trial records that include all 
pertinent observations on each of the site's trial participants. Source data should be 

Incyte Corporation  Version 1  Page 64 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  64 attributable, legible, contemporaneous, original, accurate, and complete.  Changes to 
source data should be traceable, should not obscure the original entry, and should  be 
explained if necessary (eg , via an audit trail). Source data are in general all 
information in original records and certified copi[INVESTIGATOR_122567], observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data are contained in source 
documents (original records or certified copi[INVESTIGATOR_014]).  
• Verifying that data entries are acc urate and correct by [CONTACT_108125].  
• Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF, or sent to a central vendor designated by [CONTACT_456], or as 
described in other study an d data flow manuals.  
− Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed and 
available at the investigator's site. Examples of source documents are original  
documents, data, and records (eg , hospi[INVESTIGATOR_1097], electronic hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, participants' diaries or 
evaluation checklists, pharmacy dispensing records, recorded data from 
automated instruments , copi[INVESTIGATOR_44641], microfiches, photographic negatives, microfilm or magnetic 
media, x -rays, participants' files, and e -records/records kept at the pharmacy, at 
the laboratories and at medico -technical departments involved in the clinical 
trial).  
− Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous med ical records or transfer records, 
depending on the study. Current applicable medical records must be available.  
• Sending participants' data, either as unique samples, or copi[INVESTIGATOR_014], or photographs, to be 
evaluated centrally or analyzed centrally, or both, by a qualified vendor designated by 
[CONTACT_456].  
• Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_89225].  
− Monitoring : Qualified represe ntatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan. The 
investigator must allow the study monitors to review any study materials and 
participant records at each monitoring visit.  
− Auditing : Qual ified representatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct. The 
investigator must allow the auditors  to review original source records and study 
documentation for all participants.  
Incyte Corporation  Version 1  Page 65 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  65 − Regulatory inspection : Regulatory authorities may conduct an inspection of the 
study and the site at any time during the development of an investigational 
product. The investi gator and staff are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other 
study -related documents. The investigator must immediately notify the sponsor 
when contact[CONTACT_490555] f or the purposes of conducting an 
inspection.  
11.3. Data Privacy and Confidentiality of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data protection laws 
and regulations. The investigator and the sponsor or its designee  are responsible for ensuring that 
sensitive personal information is handled in accordance with local data protection laws 
(including but not limited to HIPAA and GDPR) as applicable. Appropriate consent for 
collection, use and disclosure and/or transfer ( if applicable) of personal information must be 
obtained in accordance with local data protection laws.  
Participant names will not be supplied to the sponsor or its designee. Only the participant number 
will be recorded in the eCRF; if the participant's nam e appears on any other document (eg, 
laboratory report), it must be obliterated on the copy of the document to be supplied to the 
sponsor or its designee. Study findings stored on a computer will be stored in accordance with 
appropriate technical and organ izational measures as required by [CONTACT_89227].  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_1732] [ADDRESS_630721]  to FDA 
Regulation Title 21 CFR Part 54 – Financial Disclosure by [CONTACT_6230] (ie, "covered 
studies") are required to submit a completed Clinical Investigator Financial Disc losure form that 
sufficiently details any financial interests and arrangements that apply. For the purpose of this 
regulation, "clinical investigator" is defined as any investigator or subinvestigator who is directly 
involved in the treatment or evaluation  of research participants, including the spouse and each 
dependent child of the clinical investigator or subinvestigator. These requirements apply to both 
US and foreign clinical investigators conducting covered clinical studies.  
Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed Investigator Financial Disclosure Form. During a covered clinical study, any 
changes to the financial information previously reported by a clinical investigat or must be 
reported to the sponsor or its designee. At the conclusion of the covered clinical study, the 
clinical investigators will be reminded of their obligations. In the event that the clinical 
investigator is not reminded, they nevertheless will remai n obligated to report to the sponsor or 
its designee any changes to the financial information previously reported, as well as any changes 
in their financial information for a period of 1 year after completion of the covered clinical study.  
Incyte Corporation  Version 1  Page 66 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  66 11.5. Publication Poli cy 
By [CONTACT_89228], the investigator and their institution agree that the results of the 
study may be used by [CONTACT_456], Incyte Corporation (Incyte), for the purposes of national and 
international registration, publication, and information for medical and pharmaceutical 
professionals. Study results will be published in accordance with applicable local and national 
regulations. If necessary, the authorities will be notified of the investigator's name, address, 
qualifications, and extent of in volvement. The terms regarding the publication of study results 
are contained in the agreement signed with the sponsor or its designee. A signed agreement will 
be retained by [CONTACT_3552].  
The results of this study may be published or presen ted at scientific meetings. If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. 
This allows the sponsor to protect proprietary information and to provide comments.  
The sponsor will comply wi th the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator [INVESTIGATOR_12992].  
Authorship will be determined in line with International Committee of Medical Journal Editors 
authorship requirements.  
11.6. Study and Site Closure  
The sponsor or designee reserves the right to cl ose the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collect ed and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a  study site by [CONTACT_11004]:  
• Failure of the investigator to comply with the Protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines.  
• Inadequate rec ruitment of participants by [CONTACT_093].  
• Discontinuation of further study treatment development.  
Incyte Corporation  Version 1  Page 67 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  67 12. REFERENCES  
American Academy of Dermatology. Vitiligo: diagnosis and treatment. 
https://www.aad.org/public/diseases/a -z/vitiligo -treatment . 
 
 
 
Castanet J, Ortonne JP. Pathophysiology of vitiligo. Cli n Dermatol 1997;15:845 -851. 
Centers for Disease Control and Prevention. BMI percentile calculator for child and tee n. 
https://www.cdc.gov/healthyweight/bmi/calculator.html . 
Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and managemen t of 
vitiligo. Br J Dermatol 2008;159:1051 -1076.  
Hamzavi I, Jain H, McLean D, Shapi[INVESTIGATOR_2152] J, Zeng H, Lui H. Parametric modeling of narrowband 
UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. 
Arch Dermatol 2004;14 0:677 -683. 
Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in 
children/adolescents and adults. Int J Dermatol 2012;51:1206 -1212.  
 
 
Mohammad TF, Al -Jamal M, Hamzavi IH, et al. The vitiligo working group recommendations 
for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol 
2017;76:879 -888. 
Pandya AG, Harris JE, Lebwohl M, et al. Addition of narrow -band ultraviolet light B 
phototherapy to ruxolitinib cream in patients with vitiligo . Poster p resented at the American 
Academy of Dermatology Virtual Meeting Experience, April 23 –25, 2021, Poster 2 7636.  
Ruxolitinib Cream Investigator's Brochure, Wilmington, DE: Incyte Corporation.  
Silverberg JI, Silverberg NB. Association between vitiligo exte nt and distribution and 
quality -of-life impairment. JAMA Dermatol 2013;149:159 -164. 
Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European 
Dermatology Forum consensus. Br J Dermatol 2013;168:5 -19. 
 
 
Vitiligo Research Foundation. Treatment Guidelines. 
https://vrfoundation.org/treatment_guidelines . 
 
 
World Health Organization. WHO Model Prescribing Information: Drugs Used in Skin Diseases. 
Geneva, Switzerland: World Health Organization 1997.  

Incyte Corporation  Version 1  Page 68 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  68 APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S AND DEFINITIONS  
Definition s 
WOCBP : A woman who is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below)  
Women in the following categories are not considered WOCBP:  
• Premenarchal  
• Premenopausal with 1 of the following:a 
− Documented hysterectomy  
− Documented bilateral salpi[INVESTIGATOR_1656]  
− Documented bilateral oophorectomy  
• Postmenopausal  
− A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.  
o A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or HRT. However, in the absence of 12 months of 
amenorrhea, confirmation with 2 FSH measurements in the postmenopausal range is required.  
− Females on HRT and whose menopausal status is in doubt will be required to use [ADDRESS_630722] discontinue HRT to allow conf irmation of postmenopausal status before study enrollment.  
For male participants of reproductive potentialb 
The following methods during the Protocol -defined timeframe in Section  5.1 are highly effective:  
• Use of a male condom plus partner use of an additional contraceptive method when having penile -vaginal 
intercourse with a wo man of childbearing potential who is not currently pregnant.  
• Vasectomy with medical assessment of the surgical success (verified by [CONTACT_8786]'s review of the 
participant's medical records)  
• Sexual abstinencec 
−  Abstinence from penile -vaginal intercourse  
The following are not acceptable methods of contraception:  
• Periodic abstinence  (calendar, symptothermal, post ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea  method.  
• Male condom with cap, diaphragm, or sponge with spermicide.  
• Male and female condom used together.  
Note : Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile -vaginal 
intercourse or use a male condom during each epi[INVESTIGATOR_117492].  
Incyte Corporation  Version 1  Page 69 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  69 For female participants who are WOCBP  
The following methods during the Protocol -defined timeframe in Section  5.1 that can achieve a failure rate of less 
than 1% per year when used consistently and correctly are considered as highly effective birth control methods:  
• Combined (estrogen and progestogen conta ining) hormonal contraception associated with inhibition of 
ovulation.d 
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulationd 
− oral 
− injectable  
− implantablee 
• Intrauterine devicee 
• Intrauterine hormone -releasing systeme 
• Bilateral tubal occlusione 
• Vasectomized partnere,f 
• Sexual abstinencec 
a Documentation can come from the site personnel's review of the participant's medical  records, medical examination, or medical 
history interview.  
b If the male parti cipant has a partner with child bearing potential the partner should also use contraceptives.  
c In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as refraining from  
heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of t he 
participant.  
d Hormonal contr aception may be susceptible to interaction with the investigational medicinal product, which may reduce the 
efficacy of the contraception method.  
e Contraception methods that in the context of th is guidance are considered to have low user dependency.  
f Vasectomized partner is a highly effective method of avoiding pregnancy provided that partner is the sole sexual partner of t he 
WOCBP stu dy participant and that the vasectomized partner has received medical assessment of the surgical success.  
Source : Clinical Trials Facilitation and Coordination Group ( 2020 ). 
Incyte Corporation  Version [ADDRESS_630723] be instructed in the handling of study cream as follows:  
• Store study cream at room temperature.  
• Make every effort to apply study cream on schedule.  
• Report any missed applications.  
• Keep study cream in a safe place and out of reach of c hildren.  
• Bring all used and unused study cream tubes to the site at each visit.  
• Remove study cream from the tube in fingertip units until all of the areas to be treated 
are covered by a thin film.  
• Do not apply study cream on visit days as it will be applie d at the site under 
supervision of the site staff.  
• Do not use more than 1 tube (60 g) per week.  
• Emollients, sunscreen, or camouflage makeups should not be used within 2 hours 
after study cream application.  
• Do not apply study cream over sunscreen or camouflage makeup. These must be 
removed from the skin before application of the study cream. Any makeup remover 
must then be washed off and the skin dried before application of the study cream.  
• Participants should not take baths or showers within [ADDRESS_630724] of 
clinical trials. In line with the European Medicines Agency Guidelines on the Manage ment of 
Clinical Trials During the COVID -19 (Coronavirus) Pandemic ( 2020 ), the sponsor has issued the 
following Protocol considerations to ensure participant safety is maintained and adequate 
benefit/risk analyses are applied rel ative to the completion of study procedures and maintaining 
the investigational product supply chain.  
Recognizing the flexibility required to manage the impact of the pandemic on this clinical trial, 
additional details will be added to respective study man uals and project plan documents and 
communicated to the investigative sites as needed.  
Study Site Visits  
If local travel restrictions, isolation requirements, or the investigator's benefit/risk assessment 
determines it to be unsafe for participants to atte nd study visits at the investigational site, the site 
staff may elect to pursue the following:  
• In order to minimize participant risk, study visits (except Day 1, Week 4, Week 12, 
and Week 16 visits) may be conducted via telemedicine modalities (phone or vi deo). 
At a minimum, a review of AEs, concomitant medications, and study drug 
compliance must be completed. Periodic on -site visits should be conducted whenever 
feasible. The physician efficacy assessments must not be conducted by [CONTACT_87085].  
• Day 1, Wee k 4, and Week [ADDRESS_630725] be conducted in person, as this is the 
assessment for possible addition of NB -UVB phototherapy. These visits cannot be 
missed or conducted remotely. The investigator should document visit -window 
deviation s in the eCRF if necessary. If an out -of-window  deviation is significant 
(ie, > 4 weeks out -of-window) , the investigator should contact [CONTACT_490556].  
Investigational Medicinal Product Dispens ing and Distribution  
In order to ensure the continuity of providing their participants' clinical supplies within the 
constraints imparted by [CONTACT_47098], the site staff can decide to supply study drug to 
participants. Adequate supplies of study drug as determined by [CONTACT_490557] (eg, the stu dy pharmacy staff) 
using a third -party service if duly authorized by [CONTACT_2299]. The study site may use their own 
preferred courier, provided the courier adheres to certain standards (eg, use of personal 
protection equipment, maintenance of temperatur e-controlled transit environment), or one 
centrally contracted by [CONTACT_456].  
Clinical Trial Monitoring  
Study monitoring visits may be postponed; however, the site monitor will continue to employ 
off-site monitoring practices such as routine communication  methods (eg, phone calls, emails, 
Incyte Corporation  Version 1  Page 72 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  72 video visits) with the sites to get information on trial progress, participant status, and information 
on issue resolution. The study monitor may remotely review data entered into the EDC for 
accuracy and completeness. Re mote source data verification may be implemented with 
agreement of the principal investigator [INVESTIGATOR_312331], as applicable.  
If the study -site monitor cannot be on -site to perform the final drug accountability for 
reconciliation purposes, and the operation cannot be postponed, it may be performed by a 
pharmacist from the hospi[INVESTIGATOR_312332]/data manager with suitable 
training. The study drug can be returned to the sponsor by [CONTACT_5035][INVESTIGATOR_490532], or it 
can be des troyed in accordance with local practices, if applicable, and with sponsor approval.  
Incyte Corporation  Version [ADDRESS_630726] with the Class I ultra -high–potency 
preparations, which s hould only be used for limited time periods (2 -3 weeks). Representative 
preparations by [CONTACT_352984]. These groups may vary depending on the 
formulation and concentration and should be considered approximate. In general, ointments ar e 
more potent than creams or lotions. Potency is also increased when topi[INVESTIGATOR_427445].  
Potency  Class  Topi[INVESTIGATOR_2855] C orticosteroid  Formulation  
Ultra high  I Clobetasol propi[INVESTIGATOR_225332], 0.05%  
Diflorasone diacetate  Ointment, 0.05%  
High  II Amcinonide  Ointment, 0.1%  
Betamethasone dipropi[INVESTIGATOR_352920], 0.05%  
Desoximetasone  Cream or ointment, 0.025%  
Fluocinonide  Cream, ointment or gel, 0.05%  
Halcinonide  Cream, 0.1%  
III Betamethasone  dipropi[INVESTIGATOR_225332], 0.05%  
Betamethasone valerate  Ointment, 0.1%  
Diflorasone diacetate  Cream, 0.05%  
Triamcinolone acetonide  Ointment, 0.1%  
Moderate  IV Desoximetasone  Cream, 0.05%  
Fluocinolone acetonide  Ointment, 0.025%  
Fludroxycortide  Ointment, 0.05%  
Hydrocortisone valerate  Ointment, 0.2%  
Triamcinolone acetonide  Cream, 0.1%  
V Betamethasone dipropi[INVESTIGATOR_225334], 0.02%  
Betamethasone valerate  Cream, 0.1%  
Fluocinolone acetonide  Cream, 0.025%  
Fludroxycortide  Cream, 0.05%  
Hydrocortisone butyrate  Cream, 0.1%  
Hydrocortisone valerate  Cream, 0.2%  
Triamcinolone acetonide  Lotion, 0.1%  
Low VI Betamethasone valerate  Lotion, 0.05%  
Desonide  Cream, 0.05%  
Fluocinolone acetonide  Solution, 0.01%  
VII Dexamethasone sodium phosphate  Cream, 0.1%  
Hydrocortisone acetate  Cream, 1%  
Methylprednisolone acetate  Cream, 0.25%  
Source:  WHO 1997 . 
Incyte Corporation  Version 1  Page 74 of 74 
Protocol INCB [ZIP_CODE] -217 30 SEP 2021  
VV-CLIN -016566  74 APPENDIX  E. PROTOCOL AMENDMENT S UMMARY OF CHANGES  
Not applicable.  
Signature [CONTACT_11032]-CLIN-016566 v1.0
Signature [CONTACT_11032]-CLIN-016566 v1.0Approval
Approver
Approval
Approver
Approval
Approver
Approval
Approver
Approval
Approver
